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ABSTRACT OF DISSERTATION 
INTERACTIONS OF POST-PKS ENZYMES OF THE MITHRAMYCIN 
BIOSYNTHETIC PATHWAY 
Combinatorial biosynthesis is a powerful tool for generating new, more active 
drug analogues to combat disease. But in order for combinatorial biosynthesis to be 
employed to its full potential, a deep understanding of the enzymes that produce the 
parent molecule must be had. The goals of the work presented in this thesis are to 
characterize the reaction catalyzed by MtmW, the final enzyme in the mithramycin 
(MTM) biosynthetic pathway, and to discover the interaction between MtmW and 
MtmOIV.  
MtmW is an aldol-ketoreductase responsible for reducing the most distal 
carbonyl on the MTM pentyl side chain. It forms an octamer that has structural 
homology to the Kvβ subunits of the Kv1 potassium ion channel. While performing in 
vitro reactions with MtmW, we discovered that an inactive C-2 epimer, iso-mithramycin 
(iso-MTM), was produced. After verifying that iso-MTM was the correct product both in 
vitro and in vivo, we determined that iso-MTM isomerized spontaneously at a slow rate 
in the presence of Mg2+ and rapidly when passing through the S. argillaceus cell 
membrane. Finally, we showed that MTM DK, the product of MtmOIV, is the substrate 
for MtmW, and that MtmW could react with MTM DK without the presence of 
MtmOIV.
There are, however, weaknesses to the combinatorial biosynthesis method 
including low yields and low substrate affinity. A contributing factor to these 
weaknesses, we propose, is loss of the native protein-protein interactions (PPIs) that are 
present in the biosynthetic pathways subjected to combinatorial biosynthesis. To 
demonstrate this, we have shown that a PPI exists between MtmOIV and MtmW, and we 
have characterized the nature of this interaction using 19F NMR and covalent labeling 
strategies combined with MS/MS. 
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1.1 Mithramycin Structure and Activity  
Mithramycin (MTM) is a type II polyketide produced by Streptomyces 
argillaceus. MTM has antimicrobial activity against Gram positive bacteria, which 
suggests that its purpose is to suppress competition from other bacteria in the soil, the 
environment where S. argillaceus is found. MTM has previously been used in the 
treatment of hypercalcemia, testicular cancer, and Ewing’s sarcoma.1-3 Unfortunately, the 
prescription of MTM was halted due to hepatic, gastrointestinal, bone marrow, and renal 
toxicities.4 In 2011, the National Cancer Institute performed a high-throughput screening 
for activity against the TC-32 cell line, which carries the EWS-Fli1 fusion protein that is 
likely responsible for Ewing’s sarcoma. Of the 50,000 compounds screened, MTM was 
the most active, reducing the transcription of the luciferase reporter at concentrations as 
low as 10 nM.5, 6 Because of its toxicity and its potential for inhibiting the transcription 
process leading to Ewing’s sarcoma, MTM is a prime lead candidate to treat Ewing’s 
sarcoma, and a broad derivatization program evolved, initially focusing on combinatorial 
biosynthesis, then using medicinal chemistry derivatization strategies. 
MTM is an aureolic acid antibiotic. It consists of an aromatic, tricyclic aglycon, a 
C-3 pentyl side chain, and two oligosaccharide chains, a C-2-O attached trisaccharide
which is formed by β(1-3) linked D-deoxyhexoses, an oliose, an olivose, and a mycarose, 
and the C-6 attached disaccharide, which is made up of two β(1-3) connected olivoses. 
MTM also has C-7 C-methyl and C-1’ O-methyl groups. All of the keto groups 
remaining from the polyketide biosynthesis are reduced, save for the C-1 and C-2’ 
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carbonyls, while the C-8, C-9, C-3’, and C-4’ carbonyls were reduced to hydroxyl groups 
(Figure 1.1).7  
Figure 1.1 Mithramycin structure 
1.1.1 MTM as an SP1 inhibitor 
MTM binds to regions of GC rich DNA in a non-intercalative fashion. Its pentyl 
side chain and disaccharide interact with the DNA backbone and the aglycone and 
trisaccharide chain fit into the minor groove. In binding DNA, MTM forms a dimer 
coordinated around a divalent metal ion such as Mg2+ and DNA recognizing a minimum 
5'-X(G/C)(G/C)-3' sequence.8 The divalent metal is bound to the O-1 carbonyl and the O-
9 enolate anion of the aglycone on each of the MTM monomers. NMR experiments on 
the binding of the MTM dimer with Mg2+ on GC rich DNA show that the C-9 hydroxyl 
groups form hydrogen bonds with amine group of guanidine in the recognition sequence 
which gives MTM some of its binding specificity (Figure 1.2).8 
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Figure 1.2 MTM dimer (yellow) coordinated around Mg2+ (green) and bound to DNA 
(grey). Disaccharide, trisaccharide, and pentyl side chain present as indicated.  
A result of the binding of MTM to DNA in human cells is the inhibition of the 
transcription factor SP1. SP1 governs a large number of genes, including regulating 
cyclins, and pro–oncogenes like CLDN4 and MDM2, which are implicated in cancer 
genesis or progression. Using a zinc finger motif,  SP1 has a recognition sequence of 5'-
(G/T)GGGCGG(G/A)(G/A)(C/T)-3' on DNA9, a sequence which shares several features 
with the 5'-X(G/C)(G/C)-3' minimum recognition sequence of MTM. For this reason, 
MTM is a potent competitive inhibitor of SP1 binding. In an RT-PCR assay, 0.5 μM of 
demycarosyl-3D-β-D-digitoxosyl-mithramycin SK (EC-8042), an MTM analogue 
obtained through combinatorial biosynthesis, was sufficient to inhibit the C-MYC and 
XIAP, two downstream targets of SP1, to less than 10% of their wild type expression.10 
The SP1 inhibition by MTM has led to its use as a treatment for testicular carcinoma, and 
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has also had success in inhibiting other cancers, such as colon cancer and pancreatic 
cancer when used alone or in conjunction with other drugs.11, 12 
 1.1.2 MTM as an EWS-Fli1 inhibitor 
In addition to blocking the SP1 transcription factor, MTM also has activity toward 
Ewing’s sarcoma through an alternate mechanism of action. Ewing’s sarcoma is the 
second most common bone cancer. It affects 1-3 million people per year in western 
countries, and most of the patients are children. It has a 50% 5 year survival rate which 
drops below 30% for 10 years.13 Ewing’s sarcoma is a cancer caused by an aberrant 
translocation between chromosomes 11 and 22, which forms the fusion protein, EWS-
Fli1 (Ewing sarcoma breakpoint region 1-Friend leukemia integration 1 transcription 
factor) (Figure 1.3). In the newly generated fusion protein, EWS is the N-terminal portion 
and it forms a transactivation domain, a domain that increases gene expression. EWS acts 
as a transactivator through its association with other transcription factors, such as TFIID, 
as well as with mRNA and RNA splicing enzymes. On the C-terminal side, Fli1 is a 
transcription factor that regulates several genes, many of which are pro-oncogenes that 
are expressed during development (Figure 1.4). For example, Fli1 can repress the 
transcription retinoblastoma protein, a tumor suppressor that inhibits a cell from entering 
the S stage of the cell cycle from G1. When fused, EWS-Fli1 is more active than Fli1 
alone. This leads to abnormal gene expression and the Ewing’s sarcoma phenotype.13, 14 
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Figure 1.3 Fli1 DNA binding domain (Orange) binding to DNA (Magenta) 
(GACCGGAAGTG) (Protein Data Bank accession code: 5JVT) 
Figure 1.4 EWS-Fli1 translocation event 
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MTM binds to a GGAA repeat sequence that also makes up the recognition 
sequence for EWS-Fli1. In binding to this sequence, MTM also alters EWS-Fli1 binding 
and preventing transcription. In 2011, MTM was the best of 50,000 compounds screened 
against the Ewing’s sarcoma cell line TC-32 in a high throughput assay, with a mean IC50 
of 15 nM. Further, the MTM analogue  EC-8042, had comparable activity to MTM in 
regards to EWS-Fli1 suppression but was 130 and 32 fold less toxic, respectively, 
depending on whether the method of administration was intravenous or intraperitoneal.5, 
15-17
1.1.3 MTM and Hypercalcemia 
MTM also has been used in the treatment of hypercalcemia, particularly in 
association with Paget's disease. 18 Hypercalcemia is a condition where there is an 
unusually high concentration of calcium in the blood serum, which can lead to cardiac 
arrest or coma. It has been shown that hypercalcemia is a symptom of cancer in 5-30% of 
patients depending on cancer type. Hypercalcemia in cancer is typically caused by 
overexpression of parathyroid hormone, a hormone that normally maintains calcium 
homeostasis by stimulating osteoclast activity.18, 19 A study by Perlia et. al. involving 32 
patients with hypercalcemia brought upon by cancer, found that a 25 µg/kg dose of MTM 
significantly reduced calcium serum levels, and repeated doses stabilized levels to the 
normal range. The dose given in this study was a degree of magnitude lower than that 
given in cancer treatment, indicating an alternative mechanism than simple tumor 
suppression.20 A study of MTM on the treatment of hypercalcemia in dogs showed 
similar results. Not only did MTM lower serum calcium levels, it also inhibited 
osteoclastic activity and, increased parathyroid hormone levels.21 While the exact 
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mechanism of action of MTM in the treatment of hypercalcemia is unknown, given its 
mechanism of action in SP1 and EWS-Fli1 inhibition it is likely due to an alteration of 
transcription levels in osteoclasts.20, 21 
1.2 Mithramycin Biosynthesis 
1.2.1 MTM PKS 
Polyketide biosynthesis is analogous to fatty acid biosynthesis in primary 
metabolism as both catalyze the polymerization of acyl groups. The acyl groups, 
commonly acetate and malonate are first activated by coenzyme A. The activated acyl 
groups are joined by a series of Claisen reactions resulting a poly-β-keto ester. During the 
Claisen reactions, malonyl-CoA is decarboxylated so that a single acetate unit is added to 
the polymer, the additional CO2 only being necessary to increase the nucleophilicity of 
the α-carbon of malonyl-CoA and aid the Claisen reaction (Figure 1.5). In fatty acid 
synthesis, carried out by fatty acid synthase (FAS), each carbonyl is reduced as the 
polymer is synthesized. However in polyketide synthesis this is not the case. The fate of 
the poly-β-keto ester in polyketide synthesis is determined by the type of polyketide 
synthase (PKS) in question.22, 23 
Figure 1.5 Claisen condensation begins with enolate formation and nucleophilic attack 
on the carbonyl. The reformation of the ketone causes -OR to become a leaving group 
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Mithramycin is a type II polyketide, which means that it is produced in an 
iterative fashion by a PKS that contains an KSα and a KSβ subunit, and an acyl carrier 
protein (ACP), which in contrast to type I PKSs remains attached throughout the 
elongation. First, the phosphopantotheine functional group of ACP is primed with the 
acyl starter unit. In MTM biosynthesis, this is acetate, but several other acyl groups can 
be used. For example, malonamyl is the starter unit for tetracycline biosynthesis, while 
doxorubicin starts with a propionyl unit.24 To this tethered starter unit, 9 acetate extender 
units are added by Claisen condensation, and the poly-β-keto ester of MTM is formed. 
The KSα subunit, MtmP in the MTM pathway, catalyzes the addition of the extender 
units, typically using malonyl-CoA as a substrate, which decarboxylates during the 
reaction facilitating the condensation while adding a net total of an acetate subunit 
(Figure 1.6a).25 The length of the MTM poly-β-keto ester is determined by the KSβ 
subunit, also known as the chain length factor (CLF) and was named MtmK in the MTM 
biosynthetic pathway. The CLF determines the length of the polyketide through the size 
and geometry of the cavity where the polyketide is formed (Figure 1.6b). The growing 
acyl chain is modified by a ketoreductase (MtmTI), cyclase, and aromatase (MtmQ) and 
an oxygenase (MtmOII) to form the product, 4-demethylpremithramycinone (Figure 
1.7).25, 26
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Figure 1.6 A general type II PKS reaction using malonyl as a starter and extender unit 
malonyl is added to the phosphopantotheine coenzyme by malonylacyltransferase 
(MAT). B. The structure of the KS (Blue ribbon) and CLF (Teal spheres) in 
actinorohdin PKS (actI-ORF1,ORF2). The catalytic cysteine (yellow spheres) is on the 
KS subunit, while the pocket that determines the number of iterations is formed by the 
magenta spheres on the CLF subunit. (Protein Data Bank accession code: 1TQY)27 
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In contrast to type II PKSs, type I PKSs consist of discrete modules. An acetyl 
transfer (AT) domain loads the acyl group onto the ACP domain on a serine-attached 
phosphopantotheine, and the ketoacyl synthase (KS) catalyzes the Claisen reaction that 
elongates the acyl polymer. This is a single, minimal module. The module can also 
include ketoreductase (KR), dehydratase (DH), or enoylreductase (ER) domains to 
introduce variety to the molecule. The growing chain is passed from module to module, 
until it is released from the PKS by a thioesterase (TE) domain in the final module 
(Figure 1.8a). For example, 6-deoxyerythronolide B synthase (DEBS) produces the 
Figure 1.7 Early MTM biosynthesis steps 
11 
precursor to erythromycin and is a representative of type I PKSs. It contains six modules 
each adding methylmalonyl-CoA CoA. Modules 1 and 2 each have KR domains that 
reduce the carbonyl on the incoming acyl group, module 3 lacks a KR domain leaving the 
carbonyl intact. Module 4 contains the KR domain as well as DH and ER domains which 
results in the complete reduction of the added acyl group. Modules 5 and 6 are both 
minimal modules with the exception of the TE domain at the end of module 6 which 
cyclizes the product into the 14 member macrolactone 6-deoxyerythronolide B.28, 29 Type 
III PKSs, differ from types I and II, in that they lack an ACP domain. They rely on acyl 
CoA substrates directly and are commonly found as homodimers. As in the case of type 
II PKSs,  Type III PKS’s act iteratively, and typically produce small molecules compared 
to the other PKS types (Figure 1.8b). In addition to the canonical PKS types, there are 
hybrid systems such as type I-type II, and PKS-NRPS.30, 31 
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1.2.2 Deoxysugar Biosynthesis 
Deoxysugar moieties are a common feature in secondary metabolites and 
polyketides are no exception. The role of deoxysugars in polyketides is molecular 
recognition, increasing the binding and specificity to their target. Additionally, many 
glycosyltransferases, the enzymes responsible for adding the deoxysugars to secondary 
metabolites, are promiscuous. This makes deoxysugars and their associated 
glycosyltransferases a good tool for combinatorial biosynthesis, the derivatization of 
natural products using genetic manipulations.32 In general, deoxysugar biosynthesis 
begins with the addition of the nucleotide group thiamine diphosphate (TDP) to glucose-
Figure 1.8 A. Minimal type I PKS. Additional domains can be present in each module 
to tailor the acyl unit they add to the chain. B. A general type III PKS. 
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1-phosphate. This sugar is then oxidized at its C-4 position and dehydrated at the C-2 and
C-6 positions (Figure 1.9). From here the biosynthesis branches wildly, with
isomerizations, decarboxylations, transaminations, ketoreductions, and other reactions 
that give rise to over 90 different deoxysugars.23, 33-35 
Figure 1.9 Early deoxysugar biosynthesis. 
The role of deoxysugars in MTM is the recognition of GC-rich DNA. While we 
have no crystal structures of MTM and DNA, we do have structures of DNA with MTM 
analogues. These structures reveal that all the deoxysugars on the MTM analogue  
participate in either hydrophobic interactions or hydrogen bonding with DNA depending 
on the sugar moiety in question and the DNA sequence to which it is bound. Here I will 
describe the biosynthesis of the natural deoxysugars in MTM, and later the 
glycosyltransferases and associated combinatorial biochemistry associated with them.15, 36 
In the course of the post-PKS tailoring steps, MTM is glycosylated five times 
with three different deoxysugars. The biosynthesis of these sugars begins with glucose-1-
phosphate to which a TDP group is added by MtmD to produce TDP-D-glucose. 
Following this, MtmE, a TDP-D-glucose 4,6 dehydratase, oxidizes the substrate and 
reduces NAD+ to form TDP-D-4-keto-6-deoxyglucose and NADH respectively (Figure 
1.9).34 Next MtmV and an unknown enzyme act as a 2,3 dehydratase and C-3 
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ketoreductase, respectively, resulting in the loss of the C-2 hydroxy group (Figure 1.10). 
From this step, the sugar biosynthetic paths diverge, MtmU reduces the C-4 keto group of 
the TDP-D-4-keto-2,6-deoxyglucose such that the newly formed C-4 hydroxyl is in the R 
stereochemistry giving TDP-D-oliose as a product. MtmC is unusual in that it is a 
bifunctional enzyme. It acts as a C-3 methyltransferase, which results in TDP-D-4-keto-
mycarose, which is later reduced to TDP-D-mycarose by MtmTIII. MtmC also operates 
as a 4 ketoreductase, which reduces the C-4 hydroxyl in the S stereochemistry giving 
TDP-D-olivose (Figure 1.11).34, 37, 38  
Figure 1.10 The production of TDP-4-keto-2,6-dideoxy-D-olivose, a common 
intermediate in the biosynthesis of MTM deoxysugars. 
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Figure 1.11 The late steps of MTM deoxysugar biosynthesis. Note that MtmC catalyzes 
both the reduction and methylation of TDP-4-keto-2,6-dideoxy-D-olivose into TDP-D-
olivose and TDP-D-4-keto-mycarose respectively (Red box and red arrows).  
MtmC is also noteworthy because it processes a labile product in TDP-D-4-keto-
mycarose. The addition of the methyl group at C-3 forces the hydroxyl group into the 
axial position, putting it in close proximity to the axial TDP group on C-1. The proximity 
of these two groups encourages a nucleophilic attack from the C-3 hydroxyl to the 
phosphate group of the TDP, leading to a cyclized shunt product that is unable to be used 
by MtmGIV as a substrate. For this reason, there is likely to be an interaction between 
MtmC and MtmGIV, so that TDP-D-4-keto-mycarose can be channeled into the 
MtmGIV active site in a way that preserves its structure (Figure 1.12).38, 39 
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Figure 1.12 Proposed TDP-D-4-keto-mycarose cyclization reaction. 
1.2.3 Methylation 
4-demethylpremithramycinone, the aglycone of MTM is methylated in two
positions. First, it is O-methylated in on the C-4 hydroxyl group resulting 
premithramycinone. This is an essential step in MTM biosynthesis, as the unmethylated 
product is not be used as a substrate for other MTM enzymes in vivo. The second 
methylation is a C-methylation at the aromatic C-9 position of premithramycinone. The 
timing on this methylation is more ambiguous, in vivo knockout studies have shown that 
demethylated MTM intermediates can be isolated at any point following the first 
glycosylation in the trisaccharide synthesis, up to and including 7-demethylmithramycin 
(7-DMTM), note that later biosynthetic steps alter the numbering of MTM intermediates 
(Figure 1.13).40 
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Figure 1.13 A. MtmMI O-methylation (red). B. MtmMII aromatic C-methylation (red). 
Additional enzyme and intermediate names omitted for clarity.   
Because post-PKS steps following MtmMII methylation are promiscuous enough 
to proceed with an unmethylated product, it became a good target for combinatorial 
biosynthesis. Another member of the aureolic acid family is olivomycin A (Figure 
1.14b), it has a similar aglycone to MTM (it lacks a C-7 methyl group), but has a 
different glycosylation pattern and lacks the C-7 methyl group, and has a greater 
chemotherapeutic index than MTM. Unfortunately 7-DMTM exhibits no bioactivity 
towards Micrococcus luteus even at concentrations as high as 200 μg/ml, the same study 
showed MTM started inhibiting growth at 5 μg/ml.41, 42 Further, while 7-DMTM 
accumulated in the nucleus of HeLa cells like MTM, it has as much as a 200-fold loss in 
affinity to GC DNA sequences compared to MTM. It was thought that the C-7 methyl 
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group was necessary for the proper positioning of the mycarose sugar on the trisaccharide 
chain in the minor grove of DNA. The loss of the C-7 methyl group proved to correlate 
with a loss of activity. Durhamycin and UCH9 are two members of the aureolic acid 
family with sec-butyl groups at this position, but they are less active as chemotherapeutic 
drugs than MTM (Figures 1.14c, 1.14d). The C-7 sec-butyl group appears to push aside 
the sugars from the minor grove of DNA, and thereby decreases the amount of 
perturbation in the DNA molecule. To my knowledge, there have been no attempts of 
introduce this group onto an MTM analogue.43 
Figure 1.14 Select aureolic acid compounds. C-7 functional groups highlighted in light 
blue. 
In addition to alkyl groups, aromatic C-glycosylations are possible in type II 
polyketides. Urdamycin A (Figure 11a), for example, has an oligosaccharide chain that 
begins with a C-glycosidically linked D-olivose. Urdamycin A has both antitumor and 
antibacterial properties. Expressing the urdamycin C-glycosyltransferase UrdGT2 in S. 
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argillaceus ΔmtmMII, ΔmtmGIV and S. argillaceus ΔmtmMII, ΔmtmGI-GIV resulted in 
four new, C-glycosylated compounds, 9-C-olivosylpremithramycinone, 9-C-
mycarosylpremithramycinone, and C-4 demethyl versions of both. These novel 
compounds, however, showed little to no activity against the three tested cancer cell lines 
(Figure 11b).44-46 
Figure 1.15 A. The structure of urdamycin A B. Novel compounds from the expression 
of UrdGT2 in S. argillaceus mutants. 1. 9-C-olivosylpremithramycinone 2. 4-C-O-




Glycosyltransferases catalyze the addition of sugar moieties to molecules. In 
secondary metabolism, the deoxysugars they transfer are responsible for molecular 
recognition and are often necessary for bioactivity. The deoxysugars that 
glycosyltransferases use as a substrate are usually activated by attachment of a nucleotide 
group, TDP in MTM biosynthesis, at the C-1 anomeric carbon.23 Glycosyltransferases 
attach the sugar to nucleophiles of secondary metabolites using either an inverting or a 
retaining mechanism. The inverting mechanism, of which all MTM glycosyltransferases 
use, uses an SN2 nucleophilic attack on the anomeric carbon (Figure 1.16a). The 
nucleotide acts as a leaving group. This gives the deoxysugar inverted stereochemistry in 
regards to the attachment of the nucleotide and the substrate. The retaining mechanism 
preserves the stereochemistry of the anomeric carbon. There are many theorized 
mechanisms for retaining glycosyltransferases, two consecutive SN2 reactions known as 
double displacement, SN1, SNi, and orthogonal mechanisms have been proposed (Figure 
1.16b).47, 48
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Figure 1.16 A. Inverting glycosyltransferase (GT) mechanism. B. Proposed Retaining 
GT mechanisms. GTs in SN1, SNi, and orthogonal mechanisms participate by 
stabilizing the intermediate 
The glycosyltransferases in MTM biosynthesis can be divided into two groups, 
those that are responsible for the trisaccharide chain and those responsible for the 
disaccharide chain. In the order of the biosynthesis, MtmGIV acts first adding a D-
olivose to the 12a position of premithramycinone. MtmGIV is unusual in that it catalyzes 
the addition of the first and third deoxysugar of the trisaccharide chain, D-olivose and D-
mycarose, respectively. However, unpublished research from our lab suggests that 
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MtmGIV transfers 4-keto-D-olivose in both positions after which MtmC and MtmTIII 
finalize the chemistry while the deoxysugars are part of an MTM intermediate. Acting in 
the step between the MtmGIV glycosylations, MtmGIII adds D-oliose in the second 
position of the trisaccharide chain. The activity of these MTM analogues would be low, 
as both the trisaccharide chain and pentyl side chain are vital for MTM to bind in the 
minor groove of DNA, and MTM intermediates will not proceed through further in the 
biosynthetic pathway to produce the pentyl side chain with an incomplete trisaccharide 
chain, according to gene inactivation experiments (Figure 1.17).39, 49 
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 After the completion of the trisaccharide chain, MtmGI and MtmGII each add a D-
olivose to form the disaccharide chain at the C-8 position of premithramycin A3 (Figure 
1.18). Interestingly, inactivation of either MtmGI or MtmGII resulted in the loss of the 
entire disaccharide chain, and it was initially believed that the disaccharide was formed 
then transferred as a diolivoside to the MTM intermediate rather than two successive 
Figure 1.17 MTM trisaccharide chain biosynthesis 
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glycosylations. This was later disproven by examining the products of the inactivation of 
MtmOIV, the enzyme directly succeeding MtmGI and MtmGII in the MTM pathway. 
Among the products of the MtmOIV inactivation was 3A‐deolivosylpremithramycin B, 
proving that the D-olivoses of the disaccharide were added sequentially. By feeding this 
intermediate to S. argillaceus mutants that had MtmGI or MtmGII inactivated, it was 
found that MtmGI added the first D-olivose, and MtmGII added the second (Figure 
1.19a).50-52 The inactivity of MtmGI without MtmGII is the second example of a 
necessary PPI in the MTM biosynthetic pathway. The discovery of 3A‐
deolivosylpremithramycin B as a minor product in the ΔmtmOIV mutant also suggests the 
presence of an MtmGII, MtmOIV interaction, as the disruption of such an interaction 
would lead to intermediates leaking out of the enzyme complex into the cytosol (Figure 
1.19b).53 
Figure 1.18 Disaccharide biosynthesis 
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Figure 1.19 A. Schematic of the determination of the order of disaccharide 
glycosyltransferase enzymes. B. Proposed effect of knocking out MtmOIV if the 
enzymes form a multienzyme complex. Dashed line indicates a minor product.  
As stated before, alternating the glycosylation pattern is a fruitful strategy of 
combinatorial biosynthesis. Nowhere is this more evident than the natural occurrence of 
other aureolic acids with different deoxysugars. For example, the trisaccharide chain of 
chromomycin A3 has two D-olivose sugars and an acetylated L-chromose in place of 
MTM’s D-mycarose. Durhamycin has a tetradedeoxysugar chain containing D-olivose, 
D-oliose, followed by two D-olivose sugars (Figure 1.14). All of these secondary
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metabolites have been optimized for activity through natural selection, which encourages 
the use of combinatorial biosynthesis to generate novel compounds with altered 
saccharide patterns.53, 54 
While there have been too many experiments using combinatorial biosynthesis 
targeting the glycosylation patterns in MTM to go over each in detail, I would like to 
draw attention to a few that have shown promise for clinical application or that provide 
insight into the techniques of combinatorial biosynthesis. Heterologous expression of L-
digitoxose biosynthesis genes into S. argillaceus flooded the native glycosyltransferases 
with NDP-L-digitoxose substrate resulting in four new MTM analogues including 
demycarosyl-3D-β-D-digitoxosyl-MTM (Figure 1.20). Using a terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assays all the 
compounds were better at inducing apoptosis than MTM when used in MDA-231 breast 
cancer cells, with demycarosyl-3D-β-D- digitoxosyl-MTM showing over 20-fold more 
activity.45, 55
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Figure 1.20 Results of the heterologous expression of L-digitoxose biosynthesis genes 
into S. argillaceus. 1. Demycarosyl-3D-β-D-digitoxosyl MTM 2. Deoliosyl-3C-α-L-
digitoxosyl-MTM 3. Deoliosyl-3C-β-D-mycarosyl-MTM 
CmmA is the gene in the biosynthesis of chromomycin A3 (CMA3) that is 
responsible for acetylation of its L-chromose and D-oliose deoxysugar moieties (Figure 
1.21). The acetylation of its deoxysugars is necessary for CMA3s activity, as 
deacetylated analogues had about 100-fold less activity when tested on a panel of cancer 
cells. For this reason, it was suspected that acetylation of MTM could yield analogues 
with greater activity. MTM, demycarosyl-3D-β-D- digitoxosyl-MTM, and several 
analogues generated in other studies were fed to Streptomyces griseus, the species that 
produces CMA3, then extracted and analyzed (Figure 1.22). Seven new, acetylated 
compounds were found, all of which had a GI50 of less than 0.1 mM against the cancer 
cell lines studied. Some were more active than their nonacetylated counterparts, 
especially when tested against pancreas tumor cells. The acetyl groups were subject to 
hydrolysis, however, limiting their clinical use.43, 56, 57 
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Figure 1.21 Chromomycin A3. The acyl groups are marked with green boxes 
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Figure 1.22 Acetylated compounds generated in the S. griseus feeding experiments. 
Note that the parent compound was MTM SK in compound 7. 1. 4E-O-acetyl-
mithramycin 2. Demycarosyl-3D-β-D-digitoxosyl-3E-O acetyl-mithramycin 3. 
Demycarosyl-3D-β-D-digitoxosyl-4D-O acetyl-mithramycin 4. Demycarosyl-3D-β-D-
digitoxosyl-4E-O acetyl-mithramycin 5. Demycarosyl-3D-β-D-digitoxosyl-3E,4D-O 
acetyl-mithramycin 6. Demycarosyl-3D-β-D-digitoxosyl-3E,4E,4D-O acetyl-
mithramycin 7. 4D-O-acetyl-mithramycin SK 
1.2.5 MtmOIV, MtmW 
The final two enzymes in MTM biosynthesis are MtmOIV and MtmW, which 
catalyze the 4th ring opening using a Bayer-Villiger monooxygenase (BVMO) 
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mechanism, and reduce the distal ketone on the nascent pentyl side chain, respectively 
(Figure 1.23). These enzymes are often grouped together due to their interdependence. 
MtmOIV produces MTM DK, a labile intermediate that is quickly transformed into the 
shunt products MTM SA, MTM SK, and MTM SDK by nucleophilic attack by water on 
the β-ketones of the pentyl side chain (Figure 1.24). The protection of MTM DK to 
prevent the formation of these shunt products was the first piece of evidence that 
MtmOIV and MtmW require a PPI to produce MTM.58 
Baeyer–Villiger oxidation is rearrangement reaction resulting in the introduction 
of an oxygen adjacent to a keto group, thereby forming an ester or a lactone. The general 
mechanism of the enzyme catalyzing the Baeyer-Villiger oxidation begins with the keto 
oxygen of the substrate to be protonated and attacked by molecular oxygen. Then the 
keto group reforms and the more stably substituted group migrates leaving the new 
oxygen next to the ketone. In MtmOIV, the substrate PreB is oxygenated between C-1 
and C-2 to give a lactone intermediate. This intermediate is hydrolyzed, opening the 4th 
ring of the tetracyclic premithramycin and leaving a carboxylic group on the newly 
numbered C-2 which in turn is removed by decarboxylation, leaving the trisaccharide 
chain, also attached to C-2, with S stereochemistry (Figure 1.25).23, 58 
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Figure 1.23 The reactions of MtmOIV and MtmW 
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Figure 1.24 MTM DK shunt product formation. All reactions begin with MTM DK and 
occur on the C-3 side chain (red) 
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Figure 1.25 Baeyer-Villiger oxidation of PreB. FAD (blue) is reduced to FADH which 
in turn captures molecular oxygen. PreB (black) is attacked and a criegee intermediate 
is formed. Rearrangement and dissociation lead to PreB-lactone and hydroxylated 
FAD, the latter is regenerated by dehydration.  
The aldol-ketoreductase reaction begins with an attack on the keto group of the 
substrate by the hydride group of NADPH. The electrons that were forming the double 
bond of the ketone, in turn, attack another proton supplied from a hydroxyl group of an 
amino acid of the enzyme, typically a tyrosine. In MtmW, this reaction reduces the most 
distal of the β-ketones on the pentyl side chain, thereby preventing the formation of shunt 
products. Aldol ketoreductases catalyze their reactions using a catalytic tetrad of 
34 
histidine, tyrosine, lysine, and aspartate. Tyrosine has an partial positive charge, which is 
due to the presence of the histidine. Histidine also donates a proton to tyrosine at the 
completion of the reaction. Lysine stabilizes the charge of tyrosine and facilitates the 
interaction between tyrosine and the substrate, while aspartate stabilizes the charge of 
lysine  (Figure 1.26).59, 60 
Figure 1.26 A general aldol ketoreductase catalyzed reduction 
The MTM DK shunt products are clinically interesting, as MTM SK has 
comparable IC50 concentrations to MTM when used on a panel of ovarian cancer cell 
lines, and MTM SDK showed a 2-fold improvement in the same experiment. Both MTM 
SK and MTM SDK were also better than MTM at inhibiting SP1 governed genes.61, 62 In 
a separate experiment, MTM SK was tested against 60 cancer cell lines and was an 
average of 9-fold more active than MTM, and was 1,500-fold less active against non-
cancerous mouse 3T3 fibroblast cells. While MTM SK and MTM SDK had better 
therapeutic indices than MTM, MTM SA was relatively inactive. However, its shorter, 
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two carbon side chain terminated in a carboxylic acid group, allowed for the possibility 
of selective, semisynthetic modifications. The carboxylic acid group was reacted with 
different amino acids to form an amide linkage resulting, among others, in MTM SA-
amino acid conjugants.63 Glycine, alanine, and valine all had comparable activity to 
MTM SA, while tryptophan and phenylalanine conjugants had greater activity and 
specificity toward Ewing’s sarcoma (Figure 1.27).61-64 
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Figure 1.27 A MTM SA and its two most active amino acid conjugates, MTM SA-Trp 
and MTM SA-Phe. B. The coupling reaction between MTM SA and the amino acids 
(green box). 
1.2.6 Regulation and Resistance 
Finally, the last step in the MTM biosynthetic pathway is its export from the cell. 
This is accomplished by the ABC transporter MtrAB. MtrA is the ATP binding protein, 
which used the energy from hydrolyzing ATP to drive conformational changes in the 
transmembrane protein, MtrB, which allows for the export of MTM into the extracellular 
environment.65 An unusual fact of MTM resistance is that it seemingly relies on a single 
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mechanism. To our knowledge the only other species that contains a single resistance 
gene is Saccharopolyspora erythraea, the species that produces erythromycin. This 
suggests that it is likely that S. argillaceus contains an alternative mechanism for self-
resistance to prevent poisoning its own DNA with its own antibiotic.65, 66 
While not directly involved in MTM biosynthesis, regulation of the MTM 
pathway is important to consider in our studies. MtmR and MtrY are transcription 
factors, which regulate the production of MTM pathway enzymes, and by extension, the 
production of MTM. In the MTM pathway, MtrY is constitutively expressed and acts as a 
repressor to MtmR as well as the MTM resistance genes MtrA and MtrB. MtmR acts as a 
transcriptional activator for all seven operons in the MTM pathway and its inhibition 
keeps MTM production levels low. MtrY’s role as a repressor is reversed upon binding to 
MTM, however, the MtrY-MTM complex ceases to inhibit MtmR, and acts as a 
transcriptional activator for MtmR, MtrA and MtrB.67 The phenomenon in which MTM 
acts as its own positive regulator is known as a feed-forward system (Figure 1.28). The 
feed-forward system is not uncommon in secondary metabolite biosynthesis, particularly 
in Streptomyces species. Other examples of feed-forward mechanisms in Streptomyces 
biosynthesis include the angucycline polyketide antibiotic auricin, jadomycin, and 
landomycin as well as the anthracycline daunorubicin.68-71 The feed-forward system also 
has similarities to quorum sensing systems, where secondary metabolites are produced at 
low, basal levels until their concentration becomes sufficient to promote large-scale 
production coupled with transcriptional alterations (Figure 1.29).67-72 
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Figure 1.28 Regulation of the MTM pathway (grey). MtmR (green, arrows) acts as a 
transcription activator for the pathway but its expression is repressed  by MtrY (blue, 
inverted arrows). However when bound to MTM (orange), MtrY ceases to act as a 
repressor and switches to an transcription activator (blue arrows) for the operon 
containing MtmR. This leads to increased expression of MTM. This figure was adapted 
from Florez et. al. 2015 
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Figure 1.29 A. A hypothetical quorum system. Quorum system (QS) molecules (orange) 
and the transcriptional activator (blue) are produced at a low basal rate. When the 
concentration of QS molecules is sufficient, they bind to the activator causing it to 
begin activating transcription of the gene cluster (grey), the QS molecules, and the 
activator itself. 
1.3 Specific Aims 
In review, the biosynthesis of MTM has been well characterized and our 
understanding of the MTM biosynthetic pathway correlates with the increased 
opportunities for combinatorial biosynthesis, and by extension, better medicines. With 
this in mind, the specific aims of my research are as follows.  
Aim 1: Increase our understanding of MtmW. 
MtmW is the final enzyme in the MTM pathway and has so far only contributed 
to combinatorial biosynthesis through its absence. Also, the initial steps of our 
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investigations into MtmW revealed that it produced an unexpected epimer of MTM, iso-
MTM. Included in my first aim is to determine if iso-MTM had bioactivity, determine if 
iso-MTM was the natural product of MtmW or an artifact of the MtmW in vitro reaction, 
and to determine what, if any, mechanism of isomerization of iso-MTM into MTM. 
Aim 2: Characterize the interaction between MtmOIV and MtmW. 
There are three sets of enzymes that have putative PPIs in the MTM pathway, 
MtmC and MtmGIV, MtmGI and MtmGII, and MtmOIV and MtmW. Of these, the pair 
that has been responsible for the most promising MTM analogues is MtmOIV and 
MtmW. The evidence for the interaction between MtmOIV and MtmW includes (i) the 
apparent inactivity of MtmW in the absence of MtmOIV, (ii) that the product of MtmOIV 
is subject to degradation and therefore requires channeling to be used by MtmW, and (iii) 
intermediates and shunt products of the MTM pathway are not detected in S. argillaceus 
cultures, which suggests that enzymes in the pathway form a tightly controlled multi-
enzyme complex.  
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Discovery of a Cryptic Intermediate in Late Steps of Mithramycin Biosynthesis 
2.1 Introduction 
MtmW is an enzyme that directly influences the bioactivity of MTM in the MTM 
biosynthetic pathway, and it has been previously exploited via combinatorial biosynthesis 
to produce safer and more active analogues. MtmW also has a compelling codependence 
on MtmOIV. For these reasons, it is an excellent subject for study of the field of natural 
products. As a brief overview of this chapter, MtmW produced an unexpected C-2 epimer 
of MTM that we named iso-MTM. We determined the structure of this epimer by NMR, 
and characterized its activity. We also performed experiments to determine whether iso-
MTM was the in vivo product of MtmW, or an artifact of the in vitro reaction in which it 
was discovered. We also performed experiments in attempt to explain why iso-MTM is 
the primary product in vitro, while it is never observed in S. argillaceus cell cultures. 
Crystallization and polydispersity studies give us a clear picture of the structure of 
MtmW and inform on its role in a putative multienzyme complex, which we believe the 
post-PKS enzymes in the MTM pathway organize themselves into for efficient 
biosynthesis of MTM.  
2.2 Experimental Design and Results 
2.2.1 MtmW Crystallization 
We crystallized MtmW (ΔN3) in two crystal forms: the apo‐MtmW crystallized in 
one form (diffracting to 1.8 Å resolution) and its complex with NADP+ in the other (2.1 
Å resolution), with a similar crystal packing (Table 2.1). We determined the crystal 
structures of these two states of MtmW. The structure of an MtmW monomer (Figure 
2.1) consists of a common TIM barrel fold, which makes up most of the protein, a small 
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N‐terminal two‐stranded β‐sheet capping the TIM barrel and two extra helices outside of 
the barrel. Other short helices were also present, but their degree of disorder varied 
among monomers of the same crystal form and between the two forms. The apo‐MtmW 
crystals contained two MtmW monomers per asymmetric unit, with each monomer 
generating its own tetramer by crystal symmetry operations. In one monomer, two loops 
spanning residues 26–30 and 224–238 were not observed in the electron density map due 
to disorder. In the other monomer, in addition to two analogous loops (residues 24–30 
and 218–247), a short loop spanning residues 55–56 was also disordered. The disordered 
loops are located on the same face of the protein (in the back of the structure in Figure 
2.1).60
Figure 2.1 A monomer of MtmW. A view into the TIM barrel is shown, with the short 
N‐terminal β-sheet capping the barrel. The N‐and C‐termini are labeled as “N” and 
“C”, respectively. 
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Table 2.1 Crystallographic statistics for MtmW and its complexes with ligands 
The structure shows that the monomers of MtmW form a well-packed 
homotetramer (colored in Figure 2.2a), in which both the monomer fold and the 
tetrameric assembly are highly conserved in STM2406 and similar aldo‐keto reductases 
(AKR) as well as in Kvβ proteins. The tetramers in both crystal forms are loosely packed 
against each other (Figure 2.2b) so that their molecule, with the 4‐fold rotational 
symmetry axis running along the middle of the channel (Figure 2.2). The two helices 
lying outside of the TIM barrels are located on the periphery of the tetrameric scaffold. 
The crystal structure of MtmW in complex with NADP+ showed that the cofactor was 
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bound on the outside of the channel to each monomer (Figure 2.2), where the access to 
the nicotinamide moiety of NADPH would occur between the tetramer subunits. The 
nicotinamide moiety of the bound NADP+ exits into a large cleft (Figure 2.2 and Figure 
2.3), where substrate binding and catalysis must take place. The NADP+ binding interface 
is highly conserved among homologous proteins of known structure. As predicted from 
the sequence alignment, the catalytic tetrad universally conserved in the AKR is also 
present in MtmW at proper positions (Figure 2.4; conserved catalytic Tyr 57 is shown in 
Figure 2.5).60 
Figure 2.2 Two orthogonal views of the MtmW octamer of the MtmW‐
NADP+ complex. A) The view into the inter-subunit channel. B) The view where the 
channel is oriented along the vertical axis. The bound NADP+ is shown by purple 
sticks. 
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Figure 2.3 The crystal structure of MtmW‐NADP+‐PEG complex. NADP+ is shown by 
purple sticks, PEG (orange sticks) is well defined by the polder omit electron density 
map, contoured at 5.5σ (shown as a mesh). The residues in the putative substrate 
binding site are shown as sticks with the labels. The orientation of this MtmW 
monomer is the same as that of the similarly colored monomer in Figure 2.2a 
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Figure 2.4 The sequence alignment of MtmW and other structurally characterized 
representatives from the AKR family. These enzymes are: AKR_P.sp.JS666: AKR from 
Polaromonas sp. JS666, Kvb_rat: Kvb from Rattus norvegicus, STM2406: 3-
hydroxybutanal reductase STM2406 from Salmonella enterica serovar Typhimurium, 
Cbei_3974: AKR Cbei_3974 from Clostridium beijerinckii, YghZ_E.coli: YghZ from 
Escherichia coli, AKR_R.serpent: perakine reductase from Rauvolfia serpentina. 
Identical residues are shown in red boxes and homologous residues are shown in red 
font. The tetrad of active site residues conserved in the aldo-keto reductase (AKR) 
superfamily59 is shown by the red lollipops, and the functionally validated residues of 
the substrate binding site in the structurally similar STM240673 are shown by the green 
lollipops. The ketone oxygen of the substrate is predicted to abstract a proton from 
Tyr57 in the reduction mechanism.74 
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Figure 2.5 Views of the active sites of MtmW and STM2406. A. The active site of 
MtmW. The protein is in a similar orientation to that in Figure 2.3. B. The active site of 
STM2406 (PDB ID: 3ERP73). A cacodylate ion (yellow sticks), a 1,2-ethanediol 
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(orange sticks) and a sodium ion (a green sphere) are bound in the substrate binding 
pocket of STM2406, defined by the conserved NADPH site, the conserved catalytic 
Tyr66 and the residues whose mutations perturbed the substrate profile (Trp33, Asn65, 
Tyr100, Asn169).73 C. The active site of STM2406 in the crystal structure of STM2406-
NADP+ complex (PDB ID:5T7973). NADP+ is shown as purple sticks. 
In addition to these crystals, extensive crystallization trials were carried out to 
obtain crystals of MtmW in complex with MTM and iso‐MTM. While we did not 
observe either of these ligands in the active site of MtmW, the crystals that were grown 
with MtmW pre-incubated with iso‐MTM and NADP+ yielded strong tubular electron 
density in the putative substrate binding cleft that was best modeled by a terminal region 
of a PEG molecule, in addition to a well resolved NADP+ molecule (Figure 2.3, 2.5a, 
and 2.6). The PEG is bound in the substrate binding pocket because of its proximity to 
the nicotinamide ring of NADP+ and Tyr 57. The structurally analogous substrate binding 
pocket STM2406 (Figures 2.5b, and 2.5c) was functionally validated by mutagenesis.73 
The loops that were disordered in the apo‐ and NADP+‐bound crystal structures were all 
ordered in the MtmW‐NADP+‐PEG crystal structure. These conformational changes are 
likely coupled to MtmOIV binding, which we observed to be enhanced in the presence of 
NADPH and PreB. The PEG is bound in a hydrophobic pocket, which is large enough to 
accommodate the tricyclic mithramycin core and the 3‐side chain. Some of the residues 
lining the pocket are located on the flexible loops: Leu 24, Tyr 26, Pro 27, Val 56, Tyr 57, 
others include Met 86, and Pro 87. The cleft defined by the nicotinamide ring of NADP+ 
contains charged residues Glu 308, Arg 125, Glu 155, consistent with the polar nature of 




Figure 2.6 A zoomed-in view of the active site of MtmW in complex with NADP+ and a 
PEG region. The color scheme is the same as in Figure 2.5a 
In vertebrate Kv1 channels, each Kvβ subunit forms a complex with a T1 domain 
of the integral membrane β subunit responsible for the functional tetrameric assembly of 
the ion channel.75, 76 T1 is bound to Kvβ on the face of the tetramer analogous to the 
solvent exposed face of the MtmW octamer (Figure 2.7, top tetramer in Figure 2.2b). Kvβ 
is also an active NADPH‐dependent reductase whose dominant endogenous substrate is 
yet unknown, but the change in the redox state, even when induced by surrogate 
substrates, has been shown to regulate the channel.77 By the same logic, we propose that 
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MtmW, being the ultimate mithramycin biosynthetic enzyme, may be associated with a 
transmembrane channel to regulate the export of mithramycin.60 This work was 
performed by Drs. Oleg Tsodikov and Caixia Hu 
2.2.2 MtmW Polydispersity 
The crystal structure of MtmW showed tetrameric polydispersity. To confirm this, 
we performed size exclusion chromatography and analytical ultracentrifugation. The 
results of the size exclusion chromatography suggested an octameric assembly and this 
result was confirmed by ultracentrifugation which showed a sedimentation coefficient of 
10.8 S, which agreed with a model of MtmW octamer modeled as an oblate spheroid. 
Structurally and biochemically characterized AKR superfamily proteins that are most 
Figure 2.7 A comparison of the structures of MtmW-NADP+ complex (this study) and 
Kvβ in complex with the T1 domain (PDB ID: 1EXB15, 75). A. An octamer of MtmW is 
shown in the same view as in Figure 2.2b. B. A tetramer of Kvβ-T1-NADP+ complex. 
The Kvβ tetramer is oriented similarly to the top tetrameric layer of MtmW in panel A. 
The bound NADP+ is shown as purple sticks in both panels. 
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similar in sequence to MtmW include an octameric 3‐hydroxybutanal reductase 
STM2406 from Salmonella enterica serovar Typhimurium (36 % sequence identity) and 
a tetrameric cytosolic β subunit (Kvβ) of the Shaker family of voltage‐dependent 
potassium channels (Kv1) in vertebrates (34 % sequence identity) (Figure 2.4, Figure 
2.7).60 The ultracentrifugation was performed by Drs. Frank Herkules and Dmitri N. 
Ivanov. 
It's worth mentioning that polydispersity is highly contextual. Isopentenyl 
diphosphate isomerase in Sulfolobus shibatae forms an octamer until its substrate binds 
and causes a conformational change splitting the octamer into two tetramers (Figure 
2.8a). Similarly, phosphofructokinase in Thermus thermophilus exists as an inactive 
dimer, which forms an active tetramer in the presence of other enzymes in the glycolysis 
pathway (Figure 2.8b). In the pentose phosphate pathway of Trypanosoma brucei, the 
equilibrium of 6-Phosphogluconate dehydrogenase shifts between favoring the dimeric 
form to favoring the tetrameric form depending on the concentration of product and 
substrate (Figure 2.8c). This is not to say that we believe that MtmW in the octameric 
form does not reflect its polydispersity in vivo, only that future investigations should 
account for the possibility of tetrameric or dimeric species when making predictions 
based on MtmW’s in vivo state.78-80 
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Figure 2.8 Three factors that can effect polydispersity. A. Substrate-mediated 
conformational changes. B. PPIs with other enzymes. C. The equilibrium between the 
enzyme’s product and substrate.  
2.2.3 MtmOIV and MtmW PPI 
To confirm the existence of our proposed PPI between MtmOIV and MtmW, an 
EMSA assay and a formaldehyde crosslinking assay were performed. The pilot 
formaldehyde crosslinking assay was performed for two hours in 1% formaldehyde 
solution. While a new band did not show up at ~95 Kda, which would represent an 
MtmOIV-MtmW crosslinking, there was a mass of enzyme in the crosslinked samples 
that did not enter the gel, suggesting crosslinking had taken place. Thymidylate kinase 
(TMK) was chosen for a negative control, but exhibited a similar band that did not enter 
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the gel when subjected to formaldehyde by itself (Figure 2.9). As a follow up, a time 
course formaldehyde crosslinking assay was done with MtmOIV and MtmW for 1-16 hr. 
The results from this assay showed both MtmOIV and MtmW were removed from the 
solution in a time dependent manner, but we were unable to ascertain whether we were 
capturing a PPI or simple aggregation caused by the formaldehyde (Figure 2.10). 
Figure 2.9 The result of formaldehyde (FM) crosslinking between MtmOIV and MtmW. 
A. 1. Ladder 2. MtmOIV + MtmW 3. MtmOIV +MtmW + FM 4. MtmW + FM 5.
MtmOIV + FM 6. MtmW + TMK + FM 7. MtmOIV + TMK + FM 8. TMK + FM  B. 
Close up of the top of wells 1-5. Note the aggregation present in 3 and 5 (Black 
arrows) 
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Figure 2.10 A time course experiment with MtmOIV, MtmW and FM. 1. Ladder 2. 1 hr 
3. 2 hr. 4. 3 hr 5. Overnight. Note the aggregation at the top of each well (black arrow)
We tested whether MtmOIV and MtmW (each at 20 μM) form a complex by a 
electrophoretic mobility shift assay (EMSA) in the absence and in the presence of PreB 
and NADPH (a co‐substrate for both enzymes). (MtmOIV is strongly bound to FAD; 
therefore, addition of FAD was not necessary.) Besides the bands corresponding to 
MtmOIV and MtmW, no new band was observed at any conditions, indicating that the 
two proteins did not form a long‐lived complex. However, a distinct and reproducible 
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smear of the band corresponding to MtmW was observed in the presence of the MtmOIV 
(lanes 3–6), which migrated much more slowly. This effect was not observed in the 
absence of MtmOIV (lane 1), indicating that MtmW and MtmOIV formed a complex that 
dissociated during the initial stages of the electrophoresis. This smear was enhanced in 
the presence of either NADPH or PreB or both ligands (Figure 2.11a). The formation of 
MtmOIV‐MtmW complex in a substrate‐dependent fashion is consistent with the above 
mechanistic models of the proper sequence of reaction occurring only when the product 
of MtmOIV can be handed over directly to MtmW. We also performed this assay as a 
titration, where the concentration of MtmOIV increased while the MtmW concentration 
was kept constant at 10 μm (Figure 2.11b). In agreement with the previous experiment, 
we observed gradual weakening of the intensity of the band corresponding to the free 
MtmW upon titrating MtmOIV, indicating weak MtmOIV‐MtmW binding.60 The protein 
EMSA was performed by Drs. Oleg Tsodikov and Caixia Hu. 
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Figure 2.11 A. A Coomassie blue stained 1.7 % agarose gel showing the EMSA with 
MtmOIV (20 μM in monomers, 10 μM in dimers) and MtmW (20 μM in monomers, 2.5 
μM in octamers). The smear above the MtmW band in lanes 3–6 indicated that MtmW 
was retarded by binding MtmOIV. B. A similar gel showing a titration of MtmW (10 
μM) with MtmOIV. The fraction of free MtmW is shown below each lane. 
2.2.4 MtmW in vitro Assay 
With the knowledge that MtmOIV produces a labile intermediate, MTM DK, the 
in vitro assays of MtmW necessarily included MtmOIV as well as the cofactors NADPH 
and FAD, the NADPH being necessary for aldo ketoreductase and BVMO activity and 
the FAD necessary for BVMO activity. Surprisingly, in the presence of both enzymes, 
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only very small amounts of the expected MTM intermediates and shunt products of the 
reaction were observed, while a new HPLC peak emerged as major product in this assay. 
The production of this new compound clearly required MtmW, since this product was not 
observed in the control assays carried out in the absence of MtmW or when MtmW was 
heat‐denatured. HR‐MS showed that this new compound has an identical molecular 
weight to that of MTM, hence we named this molecule iso‐MTM. 
Figure 2.12 HPLC chromatograms of reactions catalyzed by MtmW and MtmOIV at 
pH 8.25. A) Pure PreB as standard; B) pure MTM as standard; C) PreB + MtmOIV + 
MtmW + FAD + NADPH; D) PreB + MtmOIV + FAD + NADPH; E) PreB +MtmOIV 
+ boiled MtmW + FAD + NADPH; F) PreB + MtmW + FAD + NADPH. Compounds
1, 2, and 3 are PreB, MTM, and iso-MTM, respectively. 
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2.2.5 iso-MTM NMR 
To determine the nature of the stereochemical differences between MTM and iso-
MTM, iso-MTM was purified and analyzed by NMR. The NMR spectra revealed that 
iso‐MTM is a C-2 epimer of MTM. The NMR data for iso‐MTM (10), when compared 
with those for MTM,81 revealed a distinct difference in the coupling constant of C-2‐H in 
the 1H NMR spectrum. In MTM the C-2 proton resonates at 4.78 ppm with a coupling 
constant of 11.5 Hz (trans‐coupling), whereas in iso-MTM, a coupling constant of 6.7 Hz 
(cis‐coupling) and a chemical shift of 4.40 ppm were found, indicating that iso-MTM was 
a C-2 epimer of MTM. These data also confirmed that MtmW reduced the C-4′ keto 
group, as seen in MTM (Figure 2.13).60 The NMR experiment was performed by Dr. 
Prithiba Mitra.  
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2.2.6 iso-MTM Bioassay 
The activity of iso-MTM was assayed by disk diffusion, MIC, and IC50 on the 
TC-32 Ewing’s sarcoma cell line. Salmonella enterica and Staphylococcus aureus were 
chosen to represent Gram-negative and Gram-positive bacteria, respectively. As 
expected, neither MTM nor iso-MTM was active against S. enterica, Gram-negative 
inhibition having not been previously reported. Unexpectedly, both MTM and iso-MTM 
were active against S. aureus, with iso-MTM producing a zone of inhibition of similar 
size to MTM (Figure 2.14a). An MIC assay was done using S. aureus to investigate 
Figure 2.13 Distinction between iso-MTM and MTM through NMR.  
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further. Iso-MTM had an MIC of 0.25 µg/mL versus 0.125 µg/mL for MTM, indicating 
iso-MTM had roughly half the bioactivity of MTM (Figure 2.14b). The IC50 assay using 
the EWS-Fli1 containing TC-32 cell line showed that iso‐MTM and MTM had an IC50 of 
209 nm and 45 nm, respectively (Figure 2.14c). These results were unexpected because 
the trisaccharide chain of MTM compounds is vital for activity, as it sits in the minor 
grove of DNA and provides some of the molecule’s specificity for GC-rich DNA. 
However, iso-MTM has R stereochemistry at the C-2 carbon where the trisaccharide 
attaches. This should cant the deoxysugars away from the DNA, restricting its ability to 
bind. On suspicion of iso-MTM’s apparent activity, I extracted the inhibiting MIC 
cultures and found that roughly half of the iso-MTM had isomerized into MTM (Figure 
2.15). The IC50 assay was performed by Dr. Joe Eckenrode. 
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Figure 2.14 Bioactivity of iso-MTM. A. Disk diffusion assay. Zones of inhibition are 
marked with black circles, disks are marked with grey circles. B. The IC50 assay with 
TC-32 cells. C. The MIC assay. All experiments were done in triplicate, and the data 
shown represents the average of the experiments. 
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Figure 2.15 Fate of iso-MTM in MIC samples. 
2.2.7 Macromolecular Crowding 
Macromolecular crowding (MMC) describes the native environment of an 
enzyme. The concept of MMC was developed by Minton & Wilf, when they reasoned 
that the crowding altered the polydispersity of glyceraldehyde-3-phosphate 
dehydrogenase (G3PD). G3PD forms monomers, dimers, and tetramers in solution and its 
activity increases in correlation with self-association. Because MMC increases the local 
concentration of monomers, it shifts the equilibrium of towards the more active 
tetrameric state. There are two factors to consider in oligomerization of enzymes into 
complexes. First, MMC increases the equilibrium constant for oligomerization. The 
volume displaced by the crowding agent increases the local concentration of enzyme and 
lowers the free energy required for activation for the complex, this is the transition state-
limited rate (Figure 2.16a). Second, MMC lowers the diffusion coefficient, meaning the 
rate in which the monomers encounter each other is reduced, this is known as the 
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diffusion-limited rate (Figure 2.16b). Research shows that as the amount of crowding 
agent increases, the reaction rate moves from transition-state limited to diffusion limited. 
(Figure 2.17) In practical terms, this means that there is an optimal concentration of 
macromolecules that will favor oligomerization.82, 83 
Figure 2.16 Transition state-limited rate constant and Diffusion-limited rate constant. 
A. At low concentrations of crowding agent (grey) the local concentration enzyme (red)
increases. Addition of crowding agent causes the enzymes to “crowd together” 
increasing PPIs (solid arrow). B. At high concentrations of crowding agent, diffusion 
and the rate at which the enzymes interact are reduced (dashed arrow). Addition of 
crowding agent decreases diffusion and decreases PPIs. 
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Figure 2.17 The influence of crowding agent concentration on PPI and enzyme 
reaction rates. Addition of crowding agent increases interaction (orange dashed line) 
until its concentration begins to hamper diffusion (green dashed line). Overall rate of 
interaction and reaction is shown by the black line.  
MMC can also affect the structure of proteins. Homouz et. al. showed that the 
“football-shaped” protein VlsE, a virulence factor found in Borrelia burgdorferi, changed 
shape in a manner dependent on macromolecule concentration. VlsE showed an increase 
in alpha helix structure from 50% to 80% in the presence of 400 mg/mL Ficoll 70 using 
far-UV circular dichroism.83 This phenomenon was also observed by Stagg et. al. using 
apoflavodoxin from Desulfovibrio desulfuricans, where the alpha helix content rose 20% 
and the random coil content fell 10% upon the addition of 400 mg/ml Ficoll 70.86 
Disordered regions of proteins tend to get compacted with increasing MMC. This 
compacting indirectly favors the more ordered types of secondary structure such as alpha 
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helix and beta sheet. Computer models in these studies show that the secondary and 
tertiary structures become more packed and crystalline in nature.83-87   
 The typical concentration of the intercellular environment is between 80-400 
mg/mL and is composed of proteins, sugars, lipids, nucleic acids, and other large 
molecules. In contrast, the concentration of macromolecules in our MtmOIV-MtmW in 
vitro reaction is less than 2 mg/mL. While studies on MMC typically describe differences 
in the efficiency of a reaction, it was possible that it could have been the factor 
responsible for the formation of the creation of the MTM isomer in vivo. Three scenarios 
exist in regard to the previously mentioned research. The equilibrium of the MtmOIV 
dimer or the MtmW octamer may have been altered by performing the in vitro 
experiment in an uncrowded solution, the protein interactions between MtmOIV and 
MtmW could have been altered, or the secondary structures of MtmOIV or MtmW many 
have become disordered in the uncrowded solution.  
To test the effects of MMC on the MtmOIV MtmW reaction in regard to the 
unexpected formation of iso-MTM, the reaction was performed in the presence of 100, 
200, and 300 mg/mL of PEG 8000. The concentrations were chosen based on the 
solubility of PEG 8000 and match the range of concentrations of macromolecules found 
in the intercellular environment. The reactions in PEG 8000 became less efficient as the 
concentration of crowding agent increased, as seen in the lower ratio of products to 
substrate. And they produced a similar ratio of iso-MTM to MTM; 70-85% of the 
products were iso-MTM. Overall, all the reactions with crowding agent produced a 
similar proportion of iso-MTM to MTM, leading me to conclude that loss of MMC was 
not responsible for the production of iso-MTM in my in vitro reaction (Figure 2.18). 
66 
Figure 2.18 The influence of crowding agent concentration on iso-MTM production. 
Reactions were performed as in section 2.2.4 and analyzed by LC/MS. At all 
concentrations of PEG, iso-MTM (orange) is the major product.  
2.2.8 Total Cell Assay 
If iso-MTM is an intermediate in the MTM biosynthetic pathway, an isomerase in 
S. argillaceus could have been responsible for the absence of iso-MTM in vivo. While a
dedicated isomerase has not been detected in the MTM gene cluster, several enzymes in 
the MTM pathway are bifunctional, namely MtmC and MtmGIV which are a 
methyltransferase/ketoreductase, and a non-iterative glycosyltransferase that transfers 4-
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keto mycarose and olivose to the C and E sugar positions of MTM,  respectively (Figure 
2.19). Additionally, there could be an isomerase outside the MTM gene cluster. For 
example, the elloramycin cluster in Streptomyces olivaceus lacks the genes for the 
synthesis of L-rhamnose, a deoxysugar incorporated in the final product. To detect the 
presence of an iso-MTM isomerase S. argillaceus, we reasoned that altering the PreB to 
iso-MTM reaction by omitting the purified MtmOIV and MtmW and using S. argillaceus 
cell lysate as the enzyme source, we could determine if iso-MTM was the natural product 
of the MTM biosynthetic pathway or an aberration caused by our out of context in vitro 
reaction.39, 88
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Figure 2.19 Two bifunctional enzymes in the MTM Pathway. A. MtmGIV (blue) adds 
the C and E sugars to the trisaccharide chain B. MtmC (red) acts as a 
methyltransferase/ ketoreductase in deoxysugar biosynthesis. 
Early trials of this experiment used WT S. argillaceus lysate as the enzyme 
source, but the results of these experiments were hampered by the native MTM in lysate. 
To rectify this the mutant strains S. argillaceus ∆mtmGI and S. argillaceus ∆mtmGIII 
were used as the enzyme sources as they produce premithramycin A3 and 
premithramycin A1, respectively. The results of these reactions showed that iso-MTM 
was the main product by greater than 90%. The experiments were also repeated with the 
addition of ATP to rule out an ATP-dependent isomerase, and with the addition of 
purified MtmGIII in the ∆mtmGIII strain. Iso-MTM was also the main product of these 
additional experiments (Figure 2.20).  
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From these results we concluded that there was no iso-MTM isomerase present in 
the lysate of S. argillaceus. However, the loss of an intact membrane and its associated 
osmotic and electrochemical gradient could have altered the function of a transmembrane 
or membrane dependent enzyme that was responsible for the isomerization.89  
Figure 2.20 Select results from the total cell assay experiments. S. argillaceus ΔmtmGI 
and S. argillaceus ΔmtmGIII lysates were used as enzyme sources for the PreB to iso-
MTM reaction. In all experiments, iso-MTM was the major product.  
2.2.9 Extracellular Isomerase 
The previous experiment investigated a potential isomerase or PPI binding partner 
to MtmOIV or MtmW in S. argillaceus that I suspected led to the discrepancy of the 
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products in the in vivo and in vitro reactions. This experiment did not take into account 
secreted, extracellular enzymes as the cells were pelleted and washed before lysis. 
Extracellular protein transport is a common ability for all bacterial species. For example, 
Helicobacter pylori secretes HP0175, a peptidyl prolyl cis, trans-isomerase (PPIase) as a 
virulence factor.90 PPIases isomerize proline peptide bonds from cis to trans and in the 
case of HP0175 it promotes autophagy in phagocytic cells and gastric epithelial cells 
through the conversion of the soluble human protein LC3I to its membrane bound form, 
LC3II.90 Another example of an extracellular isomerase catalyzes the conversion of 
xylose into xylulose. Though typically an intercellular enzyme, actinomycetes species 
NCL 82-5-1 secretes a soluble species of xylose isomerase when grown in xylan-
containing media.90-94  
According to these examples, it is possible that S. argillaceus secretes an 
extracellular iso-MTM isomerase. To test this, I incubated iso-MTM in a cell-free 
supernatant of S. argillaceus ∆mtmGIII that had been grown to stationary phase. The 
results of this experiment showed that iso-MTM slowly converted into MTM. Over the 
course of two days, over 80% of iso-MTM had been replaced by MTM. However, the 
conversion also occurred in a S. aureus cell-free supernatant, though to a lesser extent, 
leading me to believe that there was no extracellular isomerase as that would not have 
been present in the S. aureus supernatant. However, it did appear that there was some 
media component that was common to the R5A streptomyces media and the LB that was 
used to culture S. aureus was at least in part responsible for iso-MTM isomerization 
(Figure 2.21). 
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Figure 2.21 iso-MTM (blue) with S. argillaceus and S. aureus cell-free supernatant 
after two days incubation at 30 °C. In both cases the majority of iso-MTM epimerized 
into MTM (green) 
The mechanism we propose for iso-MTM isomerization, whether spontaneous or 
enzyme mediated, starts with the formation of an enolate at the C-2 position. The enolate 
results in planar geometry at the C-1 and C-2 carbons, and a loss of the R stereochemistry 
that defines iso-MTM. From this step, H+ attack on the si face results in MTM. The S 
stereochemistry at C-1 is energetically favorable due to the steric hindrance between the 
trisaccharide chain and the pentyl side chain at C-3. Equilibrium between the keto and 
enol form of MTM would still occur, but the MTM keto form should be vastly preferred 
after the initial enolization (Figure 2.22).  
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Figure 2.22 Proposed mechanism for iso-MTM to MTM epimerization. 
2.2.10 iso-MTM Mg2+ Assay 
As stated previously, the C-9 hydroxyl and the C-1 carbonyl of MTM coordinate 
with divalent metal ions to form a dimer. It is our hypothesis that the positive charge of 
the metal ion catalyzes the enolate formation in a pH dependent manner. The use of metal 
ions to stabilize enolates is not uncommon. Type II aldolases such as fuculose 1-
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phosphate aldolase (FPA) use Zn2+ to catalyze their reactions.  FPA to converts the keto 
group of dihydroxyacetone phosphate into the enolate form to facilitate its aldol addition 
onto the aldehyde group of lactaldehyde to form fuculose 1-phosphate.98 For an example 
of divalent metal mediated isomerases, we can look to the biosynthesis of the rare sugar 
psicose. Psicose is a C-3 epimer of fructose and is used as a sugar substitute in some 
processed foods. The enzyme D-psicose 3-epimerase isomerizes D-fructose into D-
psicose in Agrobacterium tumefaciens and Clostridium scindens, and depends on the 
presence of Mn2+ ions for catalytic activity.100, 101 D-tagatose 3-epimerase is a similar 
enzyme to D-psicose 3-epimerase in that it isomerizes a sugar using a Mn2+. In the 
proposed mechanism for D-tagatose 3-epimerase, Mn2+ coordinates with the C-2 carbonyl 
and the C-3 hydroxyl groups of D-fructose and stabilizes the enolate form of the sugar. In 
the enolate form, hydride is allowed to attack the si face of the sugar resulting in the S C-
3 stereochemistry that differentiates psicose from the R C-3 stereochemistry that defines 
fructose.95-103 
Metal-mediated isomerization reactions can also be catalyzed without the aid of 
enzymes like D-psicose 3-epimerase and D-psicose 3-epimerase. Both Ni2+ complexes 
and molybdic acid can catalyze a 1,2 C-shift of the C-3 carbons of sugar molecules 
resulting in epimerization.  Although these reactions follow a fundamentally different 
mechanism than my proposed enzyme-free Mg2+ epimerization of iso-MTM, they show 
that metal ions in solution have the ability to catalyze chemical reactions of organic 
compounds, particularly those with carbonyl functional groups.104-107  
To test if the presence of Mg2+ alone was responsible for iso-MTM isomerization, 
I incubated iso-MTM in concentrations of Mg2+ up to 50 mM, the concentration found in 
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the R5A media with which I see no iso-MTM production. The results show that iso-
MTM is converted to MTM over days in a pH and Mg2+ concentration dependent manner 
when compared to controls without Mg2+. At pH 8, with Mg2+, 57.7% of iso-MTM had 
converted to MTM compared to 9.8% in the control (Figure 2.23). While these data show 
that non-enzymatic conversion of iso-MTM is mediated by Mg2+, the level of conversion 
was still lower than that of the supernatants of S. argillaceus and S. aureus (80% and 
70%, respectively). As there is no iso-MTM present in S. argillaceus cultures (Figure 
2.24), enzymes from cell lysate produce iso-MTM, and Mg2+ ions facilitate iso-MTM to 
MTM conversion, a new hypothesis was formed. The product of MtmW is iso-MTM, 
which is isomerized upon passage through the cell membrane, via MtrAB, to MTM. Mg2+ 
or other divalent metal ion likely plays a catalytic role, as either added upon membrane 
translocation or as part of a catalytic motif in MtrAB (2.25).108  
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Figure 2.23 LC/MS analysis of the isomerization of iso-MTM in the presence of 50 mM 
Tris-HCl pH 8.0 and different concentrations of MgCl2 
Figure 2.24 Extracts of a 24 hr culture of S. argillaceus. A. Supernatant butanol 
extract. B. Cell pellet butanol extract.  
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Figure 2.25 Proposed mechanism for iso-MTM to MTM epimerization. Updated to 
include the influence of Mg2+ 
2.2.11 Whole Cell Isomerization 
To test the new hypothesis, I incubated iso-MTM with S. argillaceus ∆mtmGIII. 
The purpose of this experiment was to discover if alive, intact cells would push the iso-
MTM isomerization to completion. If the isomerization were mediated by environmental 
conditions alone, the results of this experiment would be similar to the Mg2+ assays or the 
extracellular isomerase experiments. The results showed near complete conversion of iso-
MTM to MTM by the second day. The iso-MTM peak was undetectable in the LC trace, 
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and only a small peak was observed by extracted ion chromatogram (EIC) (Figure 2.26). 
These data show that iso-MTM conversion is more efficient with intact cells present than 
in supernatant alone, and showed results that nearly mirrored my observations of S. 
argillaceus WT cultures. The results also suggest that transport of iso-MTM across the 
cell membrane is necessary for complete isomerization.  
Figure 2.26 Isomerization by intact cells. 
2.2.12 iso-MTM Cell Extraction  
Streptomyces coelicolor A3(2) produces, among many secondary metabolites, 
actinorhodin. Actinorhodin is only found intercellularly, though it is transformed into its 
lactone form, γ-actinorhodin upon export from the cell. To test if iso-MTM had 
accumulated in the cell in the same manner that actinorhodin did in S. coelicolor A3(2), 1 
mL of culture was pelleted by centrifuge and washed 3 times with buffer, lysed by 
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sonication and the results extracted with twice with equal volumes of butanol. The extract 
was exchanged with methanol and analyzed by LC/MS. No iso-MTM was detected in 
this experiment, only MTM was found. The presence of MTM in the cells was expected, 
recall from chapter 1 that the MTM pathway is governed by a feed forward mechanism, 
and that MtrY is a transcription factor that requires MTM binding for activity. These 
results suggest that iso-MTM is produced by MtmW and exported directly from the cell. 
It is likely that the putative MTM enzyme complex includes MtrAB, if we accept that the 
absence of iso-MTM in our experiment reflects the absence of iso-MTM in the cytosol 
(Figure 2.27).109  
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Figure 2.27 MTM is the only compound from the MTM pathway found in S. argillaceus 
WT cultures. This suggests that there is a complex between the PKS (blue) enzymes and 
the post-PKS (green) enzymes. Intermediates such as premithramycin A2 are never 
seen, which implies that MTM intermediates are channeled through the entire MTM 
pathway because discrete enzymes would require pools of intermediates from which to 
draw.  
2.2.13 MtmW Substrate 
Previously, we believed that MTM DK was the substrate for MtmW, and that 
MtmW was inactive in the absence of MtmOIV. Studies with MTM DK were hampered 
by its rapid degradation into the shunt products MTM SK, MTM SDK, and MTM SA.58 
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In my attempts to isolate MTM DK, I discovered a new compound using extraction and 
LC/MS at higher pHs with an mass to charge ratio of 1183 m/z (Figure 2.28). While 
attempts to characterize this compound using NMR failed, its presence was only 
observed in in vitro reactions using a Tris buffering system, leading us to speculate that it 
was a ketal adduct between Tris and either the C-2’ or C-4’ carbonyl of MTM DK 
(Figure 2.29). Using this putative MTM DK-Tris adduct in a reaction with MtmW alone 
in decreasing pHs showed its conversion to iso-MTM and the MtmOIV shunt products 
(Figure 2.30). This both supports the hypothesis that the newly isolated compound is a 
MTM DK-Tris adduct, and counters the hypothesis that MtmW is inactive without the 
presence of MtmOIV. While this evidence would also seem to go against our conclusion 
from the EMSA experiments and our belief that MtmOIV and MtmW form a PPI, the 
majority of the products in these reactions were shunt products. In vitro reactions in 
MOPS behave the same way as those in Tris, both MtmOIV and MtmW are required for 
iso-MTM production and MtmOIV alone generates only shunt products. MtmOIV shunt 
products are never found in S. argillaceus WT, suggesting that MTM DK channeling is 
still present in vitro and in vivo.  
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Figure 2.28 A. The appearance of the m/z 1183 peak from the MtmOIV-MtmW in 
vitro reaction as the concentration of formic acid (FA) in the mobile phase was 
reduced. B. The m/z 1183 peak is abolished when the buffer in the in vitro reaction is 
switched from Tris to MOPS.  
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Figure 2.29 The proposed mechanism of the formation of the MTM DK-Tris ketal 
adduct.  
Figure 2.30 Isolated MTM DK-Tris adduct was used as a substrate for MtmW in a 
range of pHs. As the pH dropped, the ketal formation was reversed, allowing MtmW 
to use MTM DK as a substrate, as shown by the formation of iso-MTM. MTM SA and 
other MtmOIV shunt products (not shown) remained major products at every tested 
pH. 
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2.3 Conclusions and Future Directions 
In this study, we have demonstrated that MtmW produces an epimer of MTM, 
iso-MTM, in its reaction. While iso-MTM is not present in cultures of S. argillaceus, it is 
the product of the combined enzymes in the MTM pathway, and is present a long as an 
intact cell membrane is missing. Macromolecular crowding was also investigated, and 
ruled out as a determinant in iso-MTM production. Our bioassay appears to show that 
iso-MTM has biological activity, however, we believe that this activity that was observed 
is only due only to its spontaneous transformation into MTM. This isomerization is rapid 
and complete when crossing the S. argillaceus cell membrane, but still appreciable under 
basic conditions and in the presence of divalent metal. And finally, the structure of 
MtmW is similar to Kvβ, the cytosolic subunit of an ion channel protein. Based on these 
data, we propose that iso-MTM is the true product of MtmW both in vitro and in vivo, 
and that it isomerizes into MTM upon travel through MtrAB as it is exported from the 
cell.  
The biological significance of iso-MTM production is unclear, but reasonable 
hypotheses can be formed. As an inactive form of MTM, iso-MTM provides protection 
from the producing strain should the putative MTM multienzyme complex be uncoupled, 
or the resistance enzymes, MtrAB, lose activity. As one of the few antibiotic producers 
with a single resistance mechanism apparent, it is likely that iso-MTM is an alternate 
form of self-protection. Production of an inactive precursor exists in the secondary 
metabolite schemes of other Streptomyces as well. Streptomyces antibioticus is a 
producer of oleandomycin, which exits the cell in an inactive, glycosylated form. 
Produced alongside oleandomycin is OleR, an extracellular glycosidase that removes the 
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inactivating glucose to produce active oleandomycin a safe distance from the S. 
antibioticus. Similarly, Streptomyces griseus and Streptomyces bikiniensis produce 
streptomycin intermediates in their phosphorylated forms until just before export from 
the cell. Neither oleandomycin nor streptomycin are as naturally self-activating as iso-
MTM though, and recall from chapter 1, MTM’s presence in the cytosol of S. argillaceus 
is required for the production of MTM (Figure 2.31). So perhaps iso-MTM is a relic of 
and older function of MTM. 
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Figure 2.31 A. As inactive iso-MTM passes through the channel formed by MtrAB, it is 
enzymatically isomerized to active MTM as a form of self-protection. B. However, 
active MTM (orange) is required for the production of more MTM via interaction with 
MtrY. This, it would seem, counters iso-MTM’s role as a self-defense mechanism. 
Translocation of MTM from the environment into the cytosol is likely not mediated 
solely by MtrAB, as non-producing S. argillaceus strains become sensitive to MTM 
when mtrA is inactivated.65  
Decho et. al. hypothesize that environmental conditions can alter quorum sensing 
molecules, giving the bacteria that reabsorb them information about their environment 
(Figure 2.32).110 In the evolutionary past of MTM its conversion into iso-MTM, coupled 
with the feed-forward mechanism facilitated by MtrY, the MTM system may have served 
as a signal molecule that detected extracellular divalent metal concentrations. The 
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production of an antibiotic that also acted as a siderophore would make an efficient 
system for sequestering iron, magnesium, zinc, and other divalent metals, or alternatively, 
neutralize divalent metals when their concentrations reach toxic levels. MTM has a high 
affinity toward divalent metals, ranging from a Kd of 1.14 × 10−8 to 5.03 × 10−11 M2 in 
Mg2+ and Fe2+, respectively.111 In this model, addition of divalent metal would cause iso-
MTM to isomerize into MTM, activate MtrY and the associated feed-forward system, 
leading to full production of the MTM pathway. Fundamentally, the ability of iso-MTM 
to activate MtrY is important to answer this question. If iso-MTM were unable to initiate 
the feed forward system, it would indicate that iso-MTM may have a larger ecological 
role beyond self-protection. In comparison to iso-MTM, actinorhodin has also been 
shown to act as an intracellular signal, regulating the genes in its own biosynthetic 
pathway, has its production increased in S. coelicolor when cultured in divalent iron, and 
can chelate divalent iron. Iso-MTM may also exist at low concentrations just outside the 
cell early in the cell culture in a medium deficient in divalent metal. Early cultures in 
media with low Mg2+ were searched for traces of iso-MTM, but we were unable to detect 
it in any of these conditions. But these were in liquid media, which is not the natural 
environment for S. argillaceus, and technical limitations prevented the rapid examination 
of solid media cultures (Figure 2.33). This is, at the moment, only speculation and outside 
the scope of our current research. But it presents an interesting question for further 
study.112-116  
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Figure 2.32 A cell produces a signal molecule that induces gene set A. When that 
signal molecule is altered by environmental conditions, it induces gene set B. The 
environmental conditions relevant to iso-MTM and MTM according to our research 
are pH changes and transition elements. Figure adapted from Decho et. al.110    
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Figure 2.33 Proposed possible alternative ecological roles of iso-MTM and MTM 
(orange). At low divalent metal concentrations (Mg2+shown here), making a lethal 
complex through chelation by MTM prevents its use from competing species (green). If 
iso-MTM rather than MTM is exported from the cell, its isomerization by divalent 
metal may be detected by S. argillaceus (blue) through its ability to bind MtrY. At high 
concentrations, MTM may protect S. argillaceus from divalent metal poisoning  
MtmW has similarity to Kvβ, a subunit of the Shaker family of voltage‐dependent 
potassium channels, which form a PPI with the enzyme that forms the ion channel, we 
propose that a PPI exists between MtmW and MtrAB. Such a channel would also, the 
experiments suggest, catalyze the isomerization of iso-MTM to MTM. Analogy for this 
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model can be found in the actinorhodin biosynthesis in S. coelicolor. The diffusible, 
lactone form of actinorhodin, known as γ-actinorhodin, is only found after passage 
through an RND transporter and in conjunction with a basic extracellular environment. A 
similar transporter‐mediated catalysis may also be present in the MTM pathway, as iso‐
MTM has not been found in S. argillaceus cultures. Alternatively, as stated above, the 
local environment around the cell may be sufficient to force isomerization. We know that 
Mg2+ is ubiquitous in the environment and essential for S. argillaceus growth. This is 
unlikely however, because early cultures of S. argillaceus show no iso-MTM, and our 
experiments show that media alone are insufficient for the complete isomerization of iso-
MTM at such timescales.  
The interaction between MtmOIV and MtmW was another intriguing result from 
this research. A PPI between the enzymes was long suspected due to the instability of 
MTM DK, the product of the MtmOIV reaction. The formaldehyde crosslinking 
experiment and the EMSA assay confirmed this interaction and showed that it was 
dependent on the binding of NADPH. This, along with the evidence for binding of 
MtmGI and MtmGII, and the requirement for TDP-D-4-keto-mycarose to be channeled 
from MtmC to MtmGIV, suggest that the MTM post-PKS pathway is organized into one 
or more multienzyme complexes. There is a large amount of literature regarding 
multienzyme complexes in primary metabolism, PKS, and NRPS pathways, but there has 
been little research done on post-PKS multienzyme complexes. Aside from the MTM 
enzymes that require a PPI mentioned above, the landomycin, gaudimycin, and 
gilvocarcin pathways all contain codependent enzymes, which are indicative of PPIs if 
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not larger multienzyme complexes.117-119 Further study in this area would be beneficial to 
further combinatorial biosynthesis efforts, and should be investigated further.117-119  
2.4 Materials and Methods 
Bacterial strains and plasmids. Mithramycin producer Streptomyces argillaceus wild-type 
strain ATCC 12956 and premithramycin B producer S. argillaceus ΔmtmOIV mutant 
strain were stocked in the lab. Escherichia coli XL1 Blue (Stratagene) and SoluBL21 
(Amsbio) were used for cloning and expression experiments, respectively. Vector 
pET28a(+) (Novagen) was used for expression in E. coli. PCR amplification and gene 
cloning PCR amplification of mtmW was carried out using Phusion High-Fidelity PCR 
Master Mix (Thermo Scientific). The primers used for cloning of the gene for protein 
overexpression were MtmW_NcoI_for (5'-
AGCCATGGAGTTCCGAAGCCTTGGCCGAAGT-3') and MtmW_XhoI_rev (5'-
AACTCGAGCTCCTCGTCGTGCACGACGGAGTC-3'). The underlined letters 
represent restriction site NcoI at the start codon and XhoI located at the predicted stop 
codon. Cycling parameters started with 1 cycle at 98 °C for 30 s, followed by a 
touchdown PCR reaction with 20 cycles, with the first cycle at 98 °C for 10 s, 70 °C for 
30 s and 72 °C for 30 s, and a decrease of 0.5 °C in each cycle afterwards. Then 10 cycles 
with an annealing temperature at 60 °C were used followed by a final elongation at 72 °C 
for 10 min and a final hold at 4 °C. The agarose gel electrophoresis was used for 
detection of DNA fragments. The PCR fragment was digested with NcoI and XhoI, and 
subsequently ligated into pET28a(+) cut by the same enzymes, resulting in plasmid 
pXY23. The plasmid was sequenced (ACGT Inc.) to confirm the sequence. The sequence 
obtained of the mtmW gene (and MtmW protein) has several differences from the prior 
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GenBank sequence for mtmW. This updated sequence was deposited with the GenBank 
accession number MK907881.60 
Premithramycin B (PreB) production and isolation. Streptomyces argillaceus ΔmtmOIV 
mutant was plated onto M2 solid media and grown for 7 days at 28 ˚C. The solid media 
was used to make a 50 mL seed culture of TSB with 7 µL 50 mg/mL apramycin, which 
was grown for 3 days at 28 ˚C in a shaking incubator. 20 mL of the seed culture was used 
to seed 400 mL R5A liquid media with 10 µL of 50 mg/mL apramycin in a 2 L flask. 
This culture was allowed to incubate for 7 days at 28 ˚C, 250 rpm after which it was 
centrifuged and the supernatant collected. 100 g/L of Amberlite® XAD16N was added to 
the supernatant was stirred overnight with 100 g/L of Amberlite XAD16N. The 
supernatant was filtered with a Whatman® 150 mm #4 filter until the Amberlite® was 
dry. The resin was stirred for 2 h with 400 mL HPLC-grade methanol and 4 filtered as 
before. The filtrate was concentrated and PreB was isolated via semi preparative HPLC.60 
Enzyme production and isolation. pXY23 was transformed into BL21 (DE3) E. coli cells 
(New England Biolabs). The cells were streaked on an LB agar plate with 50 µg/mL 
kanamycin, and an individual colony was used to start a 50 mL seed culture of LB 
(lysogeny broth) and 50 µg/mL kanamycin which was incubated overnight at 18 ˚C, 250 
rpms. 5 mL of the seed culture was added to 500 mL TB and 50 µg/mL kanamycin in a 2 
L flask, grown at 18 ˚C to OD600: 0.5, and an induced with 0.1 mM IPTG. The 
temperature was reduced to 30 ˚C and grown overnight. The culture was centrifuged, the 
cells were lysed with sonication, and purified with TALON® Metal Affinity Resin 
(Clontech Laboratories, Inc.). Dialysis was performed with a 20,000 MWCO Slide-A-
Lyzer Dialysis Cassettes (ThermoFisher Scientific) and a buffer, of 20 mM Tris-HCl, 100 
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mM NaCl, 10% glycerol, and 2 mM 2-mercaptoethanol, pH 7.5. The truncated protein, 
MtmW-9, was expressed and isolated in the same way with the following exceptions: 5’-
AGCCATGGAGTTCCGAAGCCTTGGCCGA-3’ and 5’-
AAGGATCCCTACTCCTCGTCGTCGACGA -3’ primers were used to amplify mtmW, 
and BamHI and NcoI restriction enzymes were used. The TB culture was grown at 37 ˚C 
to the OD600 of 0.5 and the incubation temperature was reduced to 30 ˚C after IPTG 
induction. MtmOIV was produced as previously described.120 Briefly, mtmOIV was 
cloned into pRSETb and used to transform BL21 (DE3)pLysS. 1 L of NZCYM with 1 
mM ampicillin and 1 mM chloramphenicol was cultured with the cells was grown to the 
OD600 of 0.5-0.7, at which time IPTG was added to the final concentration of 1 mM. 
The culture was centrifuged, the cell pellet was lysed by sonication, and the lysate was 
centrifuged and purified on TALON® Metal Affinity Resin (Clontech Laboratories, 
Inc.).60 
In vitro reaction. A 500 µL reaction was carried out in water in 2 mL microcentrifuge 
tubes with 50 mM Tris-HCl pH (7.5), 500 µM NADPH, 250 µM FAD, 5 µM MtmOIV, 
15 µM MtmW, 300 µM PreB. The reaction was incubated at 30 ˚C for 1 hr. Iso-MTM 
was isolated with 10 mL by volume Amberlite® XAD16N in an Econo-Pac® 
Chromatography Column (Bio Rad). The column was washed with 2 volumes of water 
and dried. iso-MTM was eluted in HPLC-grade methanol and purified by analytical 
HPLC using a gradient of acetonitrile in water, both containing 0.1% formic acid. The 
LC detection was carried out at 410 nm.60 
LC/MS. All of the LC/MS data in this chapter was obtained from a Waters electrospray 
LC/MS. Separation of compounds was performed using a mobile phase gradient of 30% 
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acetonitrile in water to 70% acetonitrile in water over 20 min. Unless otherwise indicated, 
the mobile phase also contained 0.1% formic acid.  
EMSA assay. The EMSA assay samples were prepared in 40 mM Tris-HCl pH 8.5 with 1 
mM NADPH, 0.5 mM PreB, 5 mM MgCl2, at concentrations of MtmOIV and MtmW 
specified in the text. The samples were incubated at 21 °C for 20 min and then run on a 
1.7% agarose gel. The gel was prepared and run in 25 mM Tris pH 8.5 and 190 mM 
glycine. Each assay was performed in duplicate. Band intensities corresponding to the 
free MtmW were quantified with Volume Tools (Bio-Rad).60 
Formaldehyde Crosslinking. All reactions were performed with 50 mM sodium 
phosphate pH (7.5), 500 µM NADPH, 250 µM FAD, 300 µM PreB, and 1% 
formaldehyde. Reactions are performed as indicated with 5 µM MtmOIV, 15 µM MtmW, 
and/or 15 µM TMK. Reactions were performed at 37 °C for the specified time period. 
The reactions were quenched in 125 mM glycine and analyzed by SDS-PAGE using a 1 
mm, 12% SDS-PAGE gel at 120 V for 75 min.   
MgCl2 isomerization assay. 100 µL aliquots of 50 mM Tris-HCl pH 4, 6, and 8 were 
prepared. To these, iso-MTM was added to 10 µM with and without 50 mM MgCl2 (or at 
specified MgCl2 concentrations). These samples were incubated at 30 ˚C for 18 hours, 
extracted with butanol, dried, and brought to a volume of 50 µL with HPLC-grade 
methanol. The samples were then analyzed by LC/MS (at 410 nm).60 
Antibiotic assays. A disk diffusion assay testing bacterial growth inhibition by iso-MTM 
was performed on LB agar media with Salmonella enterica ATCC 10708 and 
Staphylococcus aureus ATCC 6538. iso-MTM, MTM and ampicillin were diluted to 1 
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mg/mL in methanol, each filter paper disk was sterilized before the addition of 10 µL of 
iso-MTM, MTM, ampicillin, or methanol. The disks were placed on LB agar plates, and 
100 µL of cultures of S. enterica or S. aureus (at OD600 = 0.2) was evenly spread on the 
agar. The plates were incubated at 37 ˚C overnight and the zones of inhibition were 
measured by a metric ruler. An MIC assay was performed on iso-MTM by the double 
dilution method. Approximately 5 x 105 S. aureus cells were added to 1 mL LB cultures 
with iso-MTM at concentrations ranging 0.03-4 µg/mL. The cultures were incubated 
overnight at 37 ˚C and the OD600 was measured by spectrophotometer. The cultures 
originally containing 4 µg/mL iso-MTM were extracted with ethyl acetate and inspected 
by LC/MS. NMR. 1.8 mg of iso-MTM was dissolved in 180 µL acetone-d6 for NMR 
experiments with 600 MHz NMR. 1 H, HMBC, HSQC, COSY, and TOCSY NMR 
experiments were performed.60 
Analytical ultracentrifugation. Sedimentation velocity (SV) experiments were performed 
in a Beckman Optima XL-I analytical ultracentrifuge (Beckman Coulter, Indianapolis, 
IN) equipped with a 4-hole AnTi-60 rotor. Samples for analytical ultracentrifugation 
(AUC) were in 40 mM Tris pH 8.0, 100 mM NaCl, 1 mM TCEP. AUC-SV studies were 
performed with MtmW at 6 µM and 17 µM. AUC-SV experiments were carried out at 20 
°C with a rotor speed of 35,000 rpm and data collection performed in the intensity mode 
at 280 nm. About 500 scans were collected for each sample. Partial specific volumes, 
molecular masses, and van Holde-Weischet analysis were performed using the Ultrascan 
III software.121 AUC-SV datasets were analyzed with SEDFIT 16.1122 using the 
continuous size distribution c(S) model. All c(S) distributions were 6 calculated with 
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fitted f/f0 and meniscus positions. Maximum entropy regularization for all fits was 
0.95.60 
Crystallization. X-ray diffraction data collection and crystal structure determination. For 
crystallization, MtmW (N-terminal three-residue truncation, ∆N3) was further purified on 
an S200 HR Sephacryl size exclusion column (GE Healthcare) by using a BioLogic 
DuoFlow HPLC system (Bio-Rad), which had been equilibrated in 40 mM Tris-HCl, 100 
mM NaCl, 2 mM β-mercaptoethanol, pH 8.0. Fractions were collected and concentrated 
to a final concentration of 12 mg/mL using Amicon Ultra-15 centrifugal filter device 
(Millipore). The crystals of apo-MtmW were grown by vapor diffusion in hanging drops 
containing 1 μL of protein and 1 μL of the reservoir solution (0.1 M Na citrate, pH 6.0, 
16-20% (w/v) PEG 1500) and incubated against 1 mL of the reservoir solution at 21 ˚C.
To obtain crystals of MtmW with bound NADP+ or NADP+ and PEG in the active site, 
NADP+ (1 mM) or NADP+ (1 mM) and iso-MTM (0.5 mM) were added to the protein 
prior to setting the hanging drops. The crystals were gradually transferred into the 
reservoir solution additionally containing 20% (v/v) glycerol and then quickly immersed 
in liquid nitrogen. The X-ray diffraction data were collected on synchrotron beamline 
22ID at the Advanced Photon Source at the Argonne National Laboratory (Argonne, IL). 
The data were processed with HKL2000 suite.123 The crystal structure of apo-MtmW was 
determined by molecular replacement by using program Phaser with the crystal structure 
of putative oxidoreductase from Salmonella enterica (PDB ID: 3ERP)73 as a search 
model. The crystal structures of MtmW-NADP+ and MtmW-NADP+ -PEG complexes 
were determined analogously, by using the crystal structure of apo-MtmW as a search 
model. The ligands were built unambiguously into strong Fo-Fc omit electron density. 
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The model building and refinement was performed iteratively with Coot124 and 
Refmac125, respectively. The crystal structures of apo-MtmW, MtmW-NADP+ and 
MtmW-NADP+ -PEG complexes and respective structure factor data were deposited into 
the Protein Data Bank with accession codes 6OVQ, 6OVX and 6OW0.60 
Total cell assay. Lysate cultures of S. argillaceus WT, S. argillaceus ΔmtmGIII, and S. 
argillaceus ΔmtmGI were grown to stationary phase 50 mL tryptic soy broth media in 
250 mL baffled flasks. PreB was cultured and purified as previously described. The 1 mL 
reactions were carried out in protein lysis buffer (50 mM tris-HCl pH: 7.5, 50 mM NaCl, 
10% glycerol) in 2 mL Eppendorf tubes with 500 µM NADPH, 250 µM FAD, and 300 
µM PreB. The reactions were incubated at 30 ˚C for 1 hr. After the reactions were 
complete, they were extracted twice with an equal volume of butanol, evaporated and 
reconstituted with methanol. All reactions were analyzed by LC/MS in negative mode 
and analyzed at 405 nm and at 1083 m/z by extracted ion count.  
MtmW Substrate Assay. A 500 µL reaction was carried out in water in 2 mL Eppendorf 
tubes with 50 mM Tris-HCl pH (7.5), 500 µM NADPH, 250 µM FAD, 5 µM MtmOIV, 
300 µM PreB. The reaction was incubated at 30 ˚C for 1 hr. Iso-MTM was isolated with 
10 mL by volume Amberlite® XAD16N in an Econo-Pac® Chromatography Column 
(Bio Rad). The column was washed with 2 volumes of water and dried. iso-MTM was 
eluted in HPLC-grade methanol and purified by analytical HPLC. The mobile phase of 
HPLC and LC/MS was gradient of acetonitrile in water, and the pH was measured at 
about 6.5, or a gradient of acetonitrile and 8 mM ammonium acetate in water adjusted to 
pH: 5.5, as indicated. The LC detection was carried out at 410 nm. In vitro reactions done 
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in MOPS were performed as above, replacing 50 mM Tris-HCl pH (7.5) with 50 mM 
MOPS pH (7.5) 
Extraction of the putative MTM DK-Tris adduct was done using pH adjusted butanol 
(butanol was shaken overnight with an equal volume of 50 mM Tris-HCl pH (7.5), 
centrifuged and the butanol fraction reserved). Purification was done using preparative 
HPLC, the mobile phase of which was a gradient of acetonitrile and 8 mM ammonium 
acetate in water adjusted to pH: 5.5 
in vitro experiment with the putative MTM DK-Tris adduct and MtmW. 100 µL reactions 
were carried out in water in 2 mL Eppendorf tubes with 50 mM MOPS, 500 µM 
NADPH, 250 µM FAD, 15 µM MtmW, 200 µM MTM DK-Tris adduct. The pH ranged 
from 8.25 to 6.5 as indicated. 
Software. PyMol and QuteMol were used to display the structures of the proteins in this 
chapter. Chemical structures were made using ChemDraw 20.0. LC/MS chromatograms 
were generated using Waters' software, except in the case of Figure 2.23 where Prism 
software was used to compile several LC/MS experiments.  
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Interactions and Channeling of the Substrates in the Mithramycin Post-PKS Pathway 
3.1 Background 
Protein-protein interactions (PPI) are well characterized in primary metabolism but 
less studied in secondary metabolism, particularly in the case of post-PKS tailoring 
enzymes. The term metabolon describes a complex of enzymes that interact in such a 
way as to channel intermediates from one active site to another without releasing them 
into the surrounding environment. The benefits of metabolon formation include 
channeling and protecting labile intermediates, and protection of the organism from toxic 
intermediates. In cell respiration, enzymes of the glycolysis and citric acid cycle 
pathways each form complexes to sequester their respective intermediates, which can be 
used in other cell processes, for the vital role of energy production. Citrate synthase 
condenses acetyl-CoA and oxaloacetic acid into citric acid. The equilibrium of this 
reaction would make the forward direction unfeasible based on the low concentrations of 
oxaloacetic acid believed to be in the cell. This is overcome through channeling, which 
raises the local concentration of the substrates sufficiently for the reaction to proceed.127 
The principle of metabolon formation is also established in plants. Sorghum bicolour 
produces dhurrin as a secondary metabolite. This cyanogenic glucoside is channeled to 
protect the plant from the hydrolysis of p-hydroxymandelonitrile into a shunt product and 
hydrogen cyanide.126-128  
Secondary metabolon formation is of interest to the field of pharmaceutical sciences 
in the context of combinatorial biosynthesis, the process where enzymes are added, 
subtracted, or replaced to a secondary metabolite pathway with the intention of producing 
altered compounds. This process is hampered by low yields and low substrate affinity. 
99 
Increasing our knowledge of PPIs in medicinal secondary product pathways is important 
to facilitate combinatorial biochemistry, which in turn expands the chemical space of 
natural products and aids drug discovery strategies.129, 130   
In the previous chapter, we discussed the characterization of the structure of 
MtmW, the reaction it catalyzes, and its interaction with MtmOIV. The subject of this 
chapter will be an in-depth look at the interaction between MtmOIV and MtmW. From 
our previous studies, we know that MtmOIV binds to MtmW with greater affinity in the 
presence of its cofactors and substrate, PreB. We know that MtmW forms an octamer in 
vitro, and MtmOIV forms a dimer. And we also hypothesize that both MtmW and 
MtmOIV interact with other enzymes in the MTM post-PKS pathway.120  
The strategy for characterizing this part of the MTM post-PKS pathway includes 
identifying the MtmOIV, MtmW PPI interface through 19F NMR and protein 
footprinting, and identifying any additional PPI partners for each enzyme using a label 
transfer experiment.  
3.2 Experimental Design and Results 
3.2.1 19F NMR  
In order to determine the location of the PPI interface between MtmOIV and 
MtmW, 19F NMR was used. Fluorine is an excellent nucleus to study proteins using 
NMR. It is approximately the same size as hydrogen, 1.35 Å and 1.2 Å, respectively, 
meaning it does not generally perturb the structure of the enzyme.  Fluorine also is rarely 
present in biological systems, which reduces background and contaminating signals. 
Fluorine also exists in 100% abundance in the 19F isotope, which has a 1/2 spin necessary 
for NMR. It also produces signals which are about 83% the intensity of 1H NMR. 
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Because 19F is the only natural isotope for fluorine, it is relatively inexpensive in 
comparison to 15N or 13C reagents. The chemical shift of fluorine is also influenced by a 
lone pair of electrons. This means that 19F NMR is exceptionally sensitive to its local 
environment. And finally, the chemical shift of 19F NMR stretches over nearly 1000 
ppms, which somewhat ameliorates the peak broadening in larger proteins, as the peaks 
are generally farther apart than what is found in other NMR experiments using other 
nuclei.131-133 
 In our original experiment, we had planned to block the shikimate pathway of  
MtmW-expressing E. coli BL21 with glyphosate, and feed 5-fluorotryptophan in place of 
non-fluorinated tryptophan, which would have resulted in 19F-labeled MtmW. This 
strategy suffered for two reasons. The first was low production, we were unable to induce 
growth of MtmW with fluorinated tryptophan. Preliminary NMR experiments showed 
that we had no incorporation of 5-fluorotryptophan in our purified MtmW. The second 
problem was coverage. MtmW has 5 tryptophans, and most of them are buried inside the 
protein structure according to its crystal structure. MtmOIV contains 9 tryptophan 
residues, most of which are clustered in the C-terminal domain, away from the active site. 
Inspired by our lab’s success in covalent side chain labeling in our protein 
footprinting experiments, we formulated a labeling strategy to post-translationally add 
fluorine tags to the surface of MtmOIV and MtmW. The aim was to select two different 
tags, one for MtmOIV and one for MtmW, that would have different enough chemical 
shifts that we could obtain Nuclear Overhauser Enhancement (NOE) data if necessary to 
produce distance constraints to further enhance our data.  
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Acetic anhydride is often used to label the primary amine on the lysine side chain. 
My hypothesis is that substituting trifluoroacetic anhydride (TFAA) for acetic anhydride 
would produce a similar label with a trifluorinated tag. MtmW has six lysine residues, 
two of which are buried in the interface of the octamer units, one in the cavity formed by 
the octamer, and three exposed to the solvent. Of the solvent exposed lysines, K218 and 
K250 are adjacent to the active site where we expect MTM DK to be channeled. 
MtmOIV also has four solvent exposed lysines, one of which, K81, is adjacent to the two 
aspartate residues whose labeling was blocked upon co-labeling MtmOIV and MtmW in 
our preliminary protein footprinting experiments (see below, section 3.2.2). Based on 
these data, we labeled both MtmOIV and MtmW with TFAA.  
To test whether TFAA was able to label in the same manner as acetic anhydride, 
we followed a protocol for acetic anhydride labeling by Izumi et. al.134 To test the 
labeling efficiency we performed three and six rounds of TFAA labeling on MtmOIV and 
used an assay with 2,4,6-trinitrobenzene sulfonic acid (TNBSA), a reagent that detects 
free amines by the absorbance at 335 nm, and compared labeled and unlabeled MtmOIV. 
We found that after 3 rounds of labeling, 85.0% of the free amines were labeled with 
TNBSA, and after six rounds of labeling, only 78.0% of the primary amines were labeled 
with TNBSA as compared to unlabeled MtmOIV. This suggested that 15% and 22% of 
the primary amine sites were blocked from TNBSA labeling by the previous labeling 
reactions with TFAA, respectively. 
MtmW was labeled using the same procedure as described above and showed a 
TFAA incorporation of 49% of the free amines according to the TNBSA assay. However, 
when the labeled MtmW was analyzed by NMR, there were no peaks that corresponded 
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to labeled protein. As the size of a protein increases, its rotational correlation time (τc), 
the average time it takes for a molecule to rotate one radian, increases. As the τc 
increases, the peak width and signal-to-noise ratio both decrease due to more efficent 
transverse relaxation. In practical terms, this means that large proteins should have broad 
peaks when using NMR.135 The 15 kDa protein bovine protein disulphide isomerase has a 
peak width of 0.25 ppm, while the 94 kDa homodimer 3-hydroxybenzoate 6-hydroxylase 
has a peak width of about 3 ppm.136, 137 The MtmW octamer is over 280 kDa, so we 
expected our peak width to be considerably larger than 3 ppm. The results of our NMR 
experiments showed a multiplet of less than 0.1 ppm (Figure 3.1). For this reason, these 
peaks cannot be derived from our labeled MtmW, and we suspect they are from 
triflouroacetic acid that resulted from the labels disassociating from the lysines of MtmW 
(Figure 3.2).  
The absence of TFAA labeling in the literature also suggests that it is not a useful 
strategy. Acetic anhydride labeling is well documented,138, 139 and it would be reasonable 
to assume that other labs would have attempted TFAA labeling as it is the logical 
extension of acetic anhydride labeling. For these reasons, we suggest that TFAA labeling 
is not viable for 19F NMR studies.  
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Figure 3.1 19F NMR of TFAA labeled MtmW with and without MtmOIV 
Figure 3.2 A. TFAA labeling reaction. B. Proposed mechanism of TFAA label 
disassociation.  
The next attempt to covalently label MtmOIV and MtmW with a fluorinated tag was 
adapted from Abboud et. al.140 Briefly, cysteine mutants were generated on the surface of 
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MtmOIV on each face of the enzyme (Figure 3.3 A-C). These new cysteines were to be 
labeled with 3-bromo-1,1,1-trifluoroacetone (BTFA) and analyzed by 19F NMR (Figure 
3.3d). While the generation of vectors with the MtmOIV cysteine mutants was 
successful, none of these mutants could be expressed in a soluble form. We hypothesize 
that this was a result of aggregation from the formation of disulfide bonds during protein 
expression or purification. However, this project was abandoned before the expression 
conditions could be optimized due to our discovery that MtmW formed an octamer, and 
the difficulties of performing NMR on large enzyme complexes made the experiments 
unfeasible.  
Figure 3.3 A-C. Three sides of the MtmOIV dimer showing the proposed cysteine 
mutations (magenta). * indicates nearest amino acid if the mutation fell on a flexible 
loop that was not included in the crystal structure. PreB is shown as green sticks. D. 
The 3-bromo-1,1,1-trifluoroacetone (BTFA) reaction with cysteine. 
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3.2.2 Protein Footprinting 
Protein footprinting is the differential labeling of the exterior of a protein based on the 
loss of portions of surface area caused by PPIs. The methods of labeling include the 
exchange of surface exposed amide protons for deuterium, modification by hydroxyl 
radicals, and side chain  covalent labeling. The labeled proteins are then digested into 
peptides and analyzed by mass spectrometry.  
Hydrogen deuterium exchange (HDX) takes advantage of the natural exchange of 
the amide protons that occurs on the protein backbone at physiological conditions. By 
introducing deuterium to the solvent, typically in the form of D2O, the amide protons can 
exchange with deuterium, increasing the mass of each labeled position by 1.006 Da. This 
method has high resolution because the amide protons of all amino acids, apart from 
proline, can be exchanged, and as an isotope, deuteration has little effect on protein 
conformation. The method’s weaknesses chiefly involve the rapid back exchange of the 
deuterated amides to protons. This weakness can be mitigated by keeping the pH at 2.5, 
and by keeping the exchanged protein cold. Nevertheless, rapid, high-pressure liquid 
chromatography methods must be employed to capture HDX labeling, and a protease 
active in low pHs, such as pepsin, must be used for digestion into peptides.141, 142 
Hydroxyl radicals are generated using radiolysis, photolysis, or chemical 
oxidation of water using Fenton’s reagent. The hydroxyl radicals attack the side chains of 
the amino acids forming the protein based on solvent accessibility and amino acid 
identity. For example, cysteine, methionine, and tryptophan are all sensitive to hydroxyl 
radical attack while asparagine, alanine and glycine are relatively insensitive. Unlike 
HDX, the labeling is irreversible, which expands the options available for digestion and 
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analysis. Also unlike HDX, the changes in mass are more variable. Arginine, for 
example, can have a change in mass of -43.0534, +13.9793, or +15.9949 depending on 
the manner in which the hydroxyl radical attacks.143, 144 This variability can make the 
results of such experiments difficult to analyze. 
Covalent labeling uses chemical reactions to label the amino acid side chains. 
Different reactions are used to label different side chains, for example, vicinal dicarbonyl 
compounds such as 2,3-butanedione (BD) is used to label arginine, while tryptophans can 
be labeled using N-bromosuccinimide, and o‐nitrophenylsulfenyl. This specificity 
simplifies the analysis, as there are small subsets of amino acids available for labeling 
and the labels provide a single change in mass. Like hydroxyl radical labeling, there is 
very little back exchange, allowing for more freedom in choosing digesting and 
separating techniques. 
With the resources and expertise at our disposal, we have elected to use a covalent 
labeling strategy to discover the PPI interface of MtmOIV and MtmW. In our 
experiments, we labeled aspartate and glutamate with N-(3-(dimethylamino)propyl)-N′-
ethylcarbodiimide hydrochloride (EDC) and glycine ethyl ester (GEE), and histidine, 
lysine, tyrosine, serine, and threonine with diethylpyrocarbonate (DEPC).  
Several pilot experiments were performed to optimize the conditions of DEPC 
labeling, yet we experienced persistent polyethylene glycol (PEG) contamination (Figure 
3.4), which causes the suppression of the ion signal from our desired analytes and renders 
the LC/MS/MS experiment useless. There are three proposed methods by which PEG 
suppresses the ion signal, competition for charge, the decrease of evaporation of the 
mobile phase droplets, and interactions between PEG and the other analytes in the gas 
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phase.145 Regardless of the mechanism, PEG contamination prevented us from obtaining 
useful information from the DEPC labeling. We hypothesize that the PEG contamination 
came from the DEPC itself, because the materials and methods used to prepare DEPC 
samples for LC/MS/MS were common to the EDC/GEE  and label transfer experiment 
samples prepared for mass spectrometry, yet only the DEPC samples contained PEG 
contamination.  
Figure 3.4 PEG contamination in a DEPC labeled trypsin digest of MtmW. Red arrows 
highlight 44 Da intervals indicating PEG contamination.  
The EDC/GEE labeling had promising results in our pilot experiments, there was 
a clear change in the labeling pattern depending on whether the enzymes were labeled 
together or separately. Unfortunately, because of time and budget restrictions, we were 
unable to confirm the results of the pilot experiments in a statistically significant way. 
Therefore, the following merely describes our preliminary data, and the interpretation is 
contingent on further experiments confirming these results.  
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When labeled with EDC/GEE individually, 11 amino acids on MtmOIV, and 15 
amino acids on MtmW were labeled. When the labeling took place during the 
MtmOIV/MtmW reaction, 10 and 9 amino acids were labeled on MtmOIV and MtmW, 
respectively. When the enzymes were labeled together, three new labels appeared on 
MtmOIV, and four were no longer present, while on MtmW no new labels appeared and 
six were not present (table 3.1). 
Table 3.1 A summary of the EDC/GEE labeling results. The IonScore is the is the (10)-
Log10 of the probability that the observed match is a random event
Looking closer at the locations of the changes in EDC/GEE labeling of MtmOIV, 
we see that E114 is unavailable for labeling in the presence of MtmW. This is most 
likely, because it is in the active site of MtmOIV and not on the surface, due to long 
distance changes in the three dimensional structure of the enzyme as it binds to MtmW. 
The two most interesting locations on MtmOIV are D94 and D99. They are away from 
the MtmOIV dimer interface, allowing us to rule out changes in the MtmOIV/MtmOIV 
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dimer interaction, and they are close to the active site of MtmOIV. This, we suspect, is 
the footprint that forms when MtmOIV and MtmW interact. 
 The final labeling site that was abolished was E123. Along with E75 and E119, 
E123 forms part of the MtmOIV dimer interface, a location which we would expect to be 
obscured if our current dimer structures were correct. Additionally, E425 and E431 were 
not labeled until MtmOIV and MtmW were labeled together –meaning they became 
solvent-exposed upon MtmOIV binding to MtmW. These labels could arise from long 
range changes in tertiary structure, but they could also be an result of changes in the 
MtmOIV dimer interface. We also hypothesize that the dimer interface is different in 
solution than has been shown in crystallization studies.120 If MtmOIV dimerized in a way 
that included E425 and E431 and then split into monomers when it bound to MtmW, this 
would explain the appearance of labels on E425 and E431.  
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Figure 3.4 Labeling of MtmOIV. Red spheres are amino acids that are labeled only 
when MtmOIV is alone. Yellow spheres are only labeled when MtmOIV is in contact 
with MtmW. Green spheres are labeled in both conditions. Supposed PPI interface 
involving D94 and D99 (black arrows) 
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Figure 3.5 Labeling results that question the established MtmOIV dimer. E75 and 
E119 (green) appear to be blocked from labeling by the MtmOIV dimer interface. E123 
(red) is only labeled when MtmOIV is alone in solution, and E425 and E431 (yellow) 
are labeled only when MtmOIV is in solution with MtmW. For colors see Figure 3.4 
The labeling of MtmW is more intuitive but less reliable. For clarity, we can 
divide the labels on MtmW into four regions: the active site, the top, the interior, and the 
belt regions. The labels on the belt region are the least effected by the addition of 
MtmOIV, it is unlikely that MtmOIV binds in this region. Changes in the interior are 
almost certainly from changes in tertiary structure or loss of access from MtmOIV 
binding close to the gaps that feed the interior, we do not expect MtmOIV to be able to 
access the interior of the octamer. The change in labeling around the active site is 
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expected and, we believe, evidence of a protein footprint (Figure 3.6a). The labels on the 
top region of MtmW are the most ambiguous because labeling is abolished next to labels 
that appear unaffected. A closer look at the IonScores (table 3.1) show that amino acids 
in the top region, E159, E190, E192, and E306, all have lower IonScores when MtmOIV 
is present. While the IonScores do not directly correlate with the proportion of labeled or 
unlabeled amino acid, lower scores indicate a lower probability of amino acid labeling, 
and can therefore provide qualitative data on labeling percentage. From these data, we 
suspect that these amino acids are loosely associated with the MtmOIV/MtmW PPI 
interface (Figure 3.6b). This work was done with the assistance of Dr. Redding Gober.  
Figure 3.6 Labeling of MtmW. Red spheres are amino acids that are labeled only when 
MtmW is alone. Green spheres are labeled in all conditions. A. Proposed PPI interface 
B. Proposed PPI interface. Green amino acids in this area have lower IonScores when
MtmOIV is in solution. 
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3.2.3 Label Transfer 
Label transfer is a modified crosslinking experiment where a tri-functional 
crosslinking reagent is used to transfer a label from one protein to its PPI binding partner. 
In our experiments we used Sulfo-SBED (Thermofisher Scientific), which is used to 
transfer a biotin tag from one protein to another. The first functional group, N-
hydroxysuccinimide (NHS), forms an amide bond with the primary amine group of a 
lysine on the “bait” protein. Aryl azide is the second functional group and under exposure 
to ultraviolet light, it forms covalent bonds with nucleophilic or active hydrogen groups 
on the “prey” protein. A reducible disulfide separates the NHS portion of the molecule 
from the aryl azide, biotin portion. Reduction of this bond leads to the labeling of the 
prey protein. The prey proteins can be purified from the reaction using streptavidin and 
characterized using western blotting or MS/MS. In our experiments, we planned to use 
this method to identify other proteins that interacted with the MtmOIV-MtmW complex. 
In our labeling experiments MtmOIV and MtmW were used as bait proteins and S. 
argillaceus lysate was used as the source for prey proteins. In this experiment, we found 
that MtmW was able to pass the biotin label to MtmOIV, as expected (table 3.2). No 
other proteins were identified as PPI partners with MtmW, which appears to contradict 
our previous hypothesis that MtmW bound to the MtrAB channel. However, a closer look 
at the structure of MtmW reveals that only the N-terminal amine and three of the six 
lysines which react with the NHS group that is used to label the bait protein are exposed 
to the solvent on the exterior of the octamer. These primary amine groups are all 
clustered around the active site, where MtmOIV binds according to our preliminary 
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protein footprinting experiments. The remainder of the lysines are in the pocket formed 
by the octamer (Figure 3.7) 
Figure 3.7 Two views of the MtmW octamer with one monomer removed for clarity. A. 
The face of MtmW that we believe forms a PPI with MtrAB has no adjacent primary 
amines (magenta) B. The remainder of the primary amines are clustered around the 
active site defined here by the co-crystallized NADPH and polyethylene glycol 
(orange).  
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Table 3.2 A summary of the label transfer results. Score is the measure of how well the 
MS/MS data matches the sequence of the proteins that were queried. Coverage is the 
percentage of the amino acids in the protein that were identified. PSMs are the number 
of MS/MS spectra that were matched to the protein.  
Therefore our results do not contradict our earlier hypothesis, they simply confirm 
MtmOIV’s association to the MtmW active site. The label transfer experiment using 
MtmOIV as the bait protein also showed that it had a PPI with MtmW, but unexpectedly 
also showed binding to MtrA. The data from the EDC/GEE labeling suggests that 
MtmOIV interacts with the top region of MtmW (Figure 3.6b). Because of this, the N-
terminus of MtmOIV should be in range to interact with MtrA. We should be cautious 
about assigning a PPI between MtmOIV and MtrA, however. Only a single, seven amino 
acid peptide was isolated from the MtmOIV bait experiments, and this was assigned to 
MtrA at a low confidence level. Further experimentation will be necessary to confirm the 
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tentative results we found in these label transfer experiments. The label transfer 
experiments confirm the existence of the MtmOIV/MtmW PPI that was discovered in our 
previous work detailed in chapter two. Unfortunately, we were unable to establish 
definitive proof of a PPI between MtmOIV or MtmW with any adjacent enzymes in the 
pathway aside from MtrA. We believe that the primary reason for this is the number and 
location of the lysine residues that are available to react with the N-hydroxysuccinimide 
functional group of sulfo-SBED. MtmOIV and MtmW require NADPH for binding, it is 
possible that other enzymes in the complex form in a dynamic manner where the 
presence of their substrate is required to induce their PPI. For example, previous research 
shows that there is a likely PPI between MtmOIV and MtmGI and/or MtmGII (Figure 
1.19b)52, however, this PPI may be dependent on the presence of premithramycin A3, 
TDP-D-olivose, premithramycin B, or intermediates and substrates that are further 
downstream. Our experiments used crude lysate with added NADPH, FAD, and 
premithramycin B, and while we can assume all of the required components to form the 
MTM complex were present, the quantity could have been insufficient to sustain the 
complex long enough to be captured by the label transfer experiment.  
3.3 Conclusions and Future Directions 
The results from the experiments in chapter three are all preliminary, so we must be 
cautious in assigning definitive results on the interactions and interfaces between 
MtmOIV, MtmW, and other mithramycin post-PKS enzymes. We can say, however, that 
the existence of a PPI between MtmOIV and MtmW was confirmed by the label transfer 
and protein footprinting experiments that were described in this chapter. We can also 
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speculate on what our preliminary results would mean if they were supported by more 
robust data, as means to provide ideas for future research. 
Examination of the proposed PPI interface between MtmOIV and MtmW suggests 
that MtmOIV binds as a monomer to the MtmW octamer (likely in a 1:1 or 1:2 ratio) 
with the MtmOIV C-terminal domain sitting on top of the MtmW top region (Figure 3.8). 
This not only fulfills the constraints put upon the interface that were imposed by the 
protein footprinting experiment, but also puts the active sites in close proximity which is 
required for the protection of MTM DK (Figure 3.9). While there are gaps in the 
handmade docking structures, the structures do not account for the flexible nature of 
proteins in solution. The C-terminal domain and the middle domain, from T183 to A275, 
of MtmOIV appear to be especially mobile.  
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Figure 3.8 Three angles on the proposed PPI between MtmOIV (blue) and the MtmW 
octamer (grey). This Figure only shows a single MtmOIV for clarity. Red spheres are 
amino acids that are labeled only when MtmOIV or MtmW are alone. Yellow spheres 
are only labeled when MtmOIV is with MtmW. Green spheres are labeled in all 
conditions. Note: This Figure was docked by hand, the only data that were considered 
were the proximity of the active sites, and the results from the label transfer and 
protein footprinting experiments.  
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Figure 3.9 Detail on the active sites of MtmOIV and MtmW in the proposed PPI model. 
MTM DK travels from the active site of MtmOIV (blue) to the active site of MtmW 
(grey). The magenta sticks are co-crystallized PreB with MtmOIV and co-crystallized 
NADPH and PEG with MtmW.  
Expanding on the homology between MtmW and the β subunit of Kv1 potassium 
channels can help us explain the results of the appearance of MtrA in the label transfer 
experiments where MtmOIV is the bait protein. If we suppose that the MtmW interaction 
with MtrAB is similar to the structure of the Kv1 potassium ion channel, and the 
proposed PPI interface between MtmOIV and MtmW is correct, MtrA should interact 
with MtmOIV (see Figure 3.10 for a model). In summary, the proposed PPI interface 
agrees with both the experiments in this chapter, as well as the requirement to channel 
MTM DK between the active site of MtmOIV and the active site of MtmW. 
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Figure 3.10 The Kv1 potassium ion channel (PMDB structure: 2A79). The Kvβ subunit 
(green) is structurally homologous to MtmW. The remainder of the Kv1 ion channel 
(purple) may also be homologous to the MTM pathway enzymes which are listed on the 
right. The proposed MtmOIV binding site on the left (red box) would fit into this system 
in a manner where is is accessible to MtrA, which is in agreement with our label 
transfer data 
Future directions for this project include verifying the preliminary data, and 
expanding the experiments to other enzymes in the MTM pathway that are known to have 
PPIs. To confirm the preliminary data, the protein footprinting experiments should be 
optimized and expanded to include BD labeling. A more rigorous crosslinking strategy 
could also be employed to find the PPI interface. A trypsin digestion and LC/MS/MS 
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analysis of the formaldehyde crosslinked MtmOIV/MtmW samples from chapter 2 may 
give interesting results, as would the mass spectrometry of the label transfer experiment 
before the crosslinker was reduced.  
The other enzymes in the MTM that should be investigated for PPIs are MtmC 
and MtmGIV, and MtmGI and MtmGII. Recall from chapter 1 that MtmC produces an 
instable intermediate, TDP-D-4-keto-mycarose, that cyclizes if it is not protected. This 
vulnerable intermediate requires channeling from MtmC to MtmGIV to prevent the 
formation of shunt products. MtmC and MtmGIV are also bifunctional enzymes whose 
reactions are separated by MtmGIII and MtmMII. MtmTIII also acts directly after the 
second MtmGIV reaction. Because of the complex order in which these enzymes act, it is 
likely that one or more of these enzymes are also in a complex with MtmC and MtmGIV 
(Figure 3.11).  
Figure 3.11 A schematic of the proposed MTM trisaccharide synthesis complex. 
We also know that MtmGI and MtmGII form a complex, MtmGI is nonfunctional 
without MtmGII. The MtmGI/MtmGII complex also interacts with MtmOIV because S. 
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argillaceus mtmOIV knockouts disrupt the interaction between MtmOIV and 
MtmGI/MtmGII and 3A‐deolivosylpremithramycin B is released and is able to be 
detected in extracts, so it is likely that MtmGI and MtmGII are part of the MtmOIV and 
MtmW complex as well (Figure 3.12) 
Figure 3.12 A schematic of the proposed MTM complex involving MtmGI-MtrB. MtmW 
is shown as a tetramer for clarity, we currently hypothesize that MtmW remains an 
octamer in vivo. 
3.4 Materials and Methods 
Enzyme production and isolation. MtmOIV and MtmW were isolated as previously 
described. Briefly, mtmOIV and mtmW were ligated into pET28a, and transformed into E. 
coli BL21. Transformants were grown in LB medium at 37 °C to OD600: 0.5-0.7 when 
they were induced with 0.1 mM IPTG. The cultures were grown overnight at 30 °C and 
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when they were centrifuged and the cells lysed by sonication. The lysates were purified 
with TALON® Metal Affinity Resin (Clontech Laboratories, Inc.), and dialyzed to 
remove imidazole. All mutants were constructed using overlap PCR, and expressed and 
purified in the same manner 
Enzyme Labeling. The enzymes that were labeled in the protein footprinting assays, 
MtmOIV and MtmW, were labeled individually or labeled together in solution. To match 
the quality of the data from the LC/MS/MS of the co-labeled enzymes, individually 
labeled enzymes were pooled after quenching and before trypsin digestion. Unless 
otherwise specified, the ratio of MtmOIV to MtmW was 1:2 based on optimization of the 
in vitro activity assay of MtmW that is described on page 88 of this document. In the 
activity assay we found that iso-MTM was the sole product of the MtmOIV, MtmW 
complex at a ratio of 1:2 and formation of shunt products appeared as the proportion of 
MtmW was reduced from this point. The use of the 1:3 ratio in the activity assay was to 
ensure that there were no shunt products present even if a portion of the MtmW degraded 
in storage. 
 Lysine residues of the enzymes were labeled with trifluoroacetic anhydride (TFAA). 
MtmOIV or MtmW was suspended in 200 mM phosphate buffer pH: 8, with 3% glycerol, 
100 mM NaCl, and diluted to 10 μM. 100 mM TFAA was freshly prepared by diluting 
into 200 mM phosphate buffer pH 8. Equal volumes of 100 mM TFAA and 10 μM 
enzyme solution were combined and allowed to react for 20 min at 4 °C, after which the 
enzyme was exchanged into fresh buffer by centrifugal filtration. This process was 
repeated 6 times. Labeling coverage was assayed using TNBS according to the 
manufacturers protocol (ThermoScientific Catalog # 28997).  
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Aspartate and glutamate were labeled using EDC/GEE according to the following 
protocol. Each 300 µL reaction was done in 25 mM MOPS, pH: 7.4 and had a final 
concentration of 6 µM of MtmOIV and/or 12 µM MtmW, 10 mM NADPH, 10 mM PreB, 
and had a GEE/EDC/total protein concentration of 1,500:60,000:1. Samples were 
incubated at room temperature for 30 min, and quenched by adding formic acid to a final 
concentration of 0.1% v/v.  
Histidine, lysine, tyrosine, serine, and threonine residues were labeled using DEPC 
according to the following protocol. Each 500 µL reaction was done in 20 mM MOPS, 
pH: 7.4 and had a final concentration of 1 µM of MtmOIV and/or 2 µM MtmW, 10 mM 
NADPH, 10 mM PreB, and 26.4 µL of DEPC. This was incubated at 37 °C for 1 minute, 
shaking. The reaction was quenched with 5 µL of 10 mM imidazole.  
The labeled enzymes were digested with trypsin, desalted, and analyzed by LC/MS/MS 
in the manner described below. 
Digestion. Enzymes were denatured and cysteine residues were blocked using 14 mM  
iodoacetamide at room temperature in the dark for 30 min, the reaction was quenched 
using 5.2 µL 0.5 M DTT for 15 min. 100 µL immobilized trypsin was washed and 
resuspended in 200 µL 25 mM tris pH 7.8. Labeled enzyme was concentrated to 100 µL 
and added to the immobilized trypsin and incubated at 37 °C for 2 hours. Immobilized 
trypsin was removed by centrifugation. 26 µL of 2.5% TFA was added to 650 µL of 
digested protein for a final concentration of 0.1%. The digested enzyme was desalted 
using a ZipTip (Sigma Catalog # ZTC04S096) using the manufacturer’s instructions.  
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19F NMR. In general, 2 mg of MtmW was suspended in 300 µL of NMR buffer (100 µM 
tris-HCl, 50 mM NaCl, 3% glycerol). MtmOIV was added to a ratio of 2:1 of MtmOIV to 
MtmW. Experiments were attempted using the following combinations of labeled and 
unlabeled enzyme, unlabeled MtmW with TFAA labeled MtmOIV and TFAA labeled 
MtmW with unlabeled MtmOIV. 
Label Transfer. Label transfer experiments were performed using Sulfo-SBED (Sulfo-N-
hydroxysuccinimidyl-2-(6-[biotinamido]-2-(p-azido benzamido)-hexanoamido) ethyl-
1,3'-dithioproprionate) Biotin Label Transfer Kit (ThermoScientific). Add 10 µL of 
dissolved Sulfo-SBED Reagent to 1 mg of bait protein in 200 mM phosphate buffer pH: 
8, with 3% glycerol, 100 mM NaCl. The reaction was incubated for 60 minutes at 4 °C.  
The buffer was exchanged 3 times using centrifugal filtration to remove excess non-
reacted Sulfo-SBED from the labeled bait protein. The bait protein was added to 15 mL 
of S. argillaceus cell lysate. To encourage binding, The mixture was allowed to react for 
5 min, after which it was exposed to 365 nm ultraviolet light for 15 minutes. An excess  
of DTT was added to the reaction to cleave the crosslinker, and the result was purified on 
streptavidin resin. The enzymes were then separated by SDS-PAGE (1 mm, 12% gel run 
at 120 V for 90 min.) or digested with immobilized trypsin (ThermoFisher Catalog 
#20230) according to the manufacturer’s instructions. The digested enzyme was desalted 
using a ZipTip (Sigma Catalog # ZTC04S096) using the manufacturer’s instructions. The 
resulting peptides were sent to the University of Kentucky Proteomics Core Facility to be 
analyzed by LC/MS/MS. 
LC/MS/MS. Samples were digested with trypsin and desalted as described above. The 
samples were submitted to the University of Kentucky’s Proteomics Core Facility for 
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LC/MS/MS analysis. The tryptic samples were used directly for LC-MS/MS analysis. 
MS data sets were searched in MASCOT146 against a custom database containing only 
the sequences of MtmW and MtmOIV in the case of the protein footprinting experiments, 
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